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CHAPTER 1 
GENERAL INTRODUCTION OF THE EPSTEIN-BARR VIRUS 
1.1 INTRODUCTION 
Epstein-Ban· virus (EBV), the causative agent of infectious mononucleosis (IM) was 
discovered in 1964 by electron microscopy in a cell line derived from a Burkitt's lymphoma 
(BL) (1). Infection with EBV appears to be common, world-wide in distribution and largely 
subclinical in early childhood. Its causal role in infectious mononucleosis (IM) is well 
documented and the disease is detected most frequently in late adolescence or early adulthood 
(2-4). In addition, an association between EBV and African BL and between EBV and 
nasopharyngeal carcinoma (NPC) has been suggested by seroepidemiologic data and by the 
detection of the EBV genome in cells from both tumors (4-8). The X-linked 
lymphoproliferative syndrome (XLP) is caused by a mutation on the X-chromosome which 
results in an abnormal immune response after infection with EBV (9,10). 
Like other herpes viruses, EBV may also be reactivated in the immunologically compromised 
host. These individuals often handle EBV quite well (11). However, EBV induced 
lymphoproliferations or EBV-carrying lymphomas have been recently noted in patients with 
both primary and acquired immunodeficiencies (4,5,12). Hairy leukoplakia in AIDS patients, 
with epithelial EBV replication results in a benign epithelial proliferation (13). Another 
category of possible EBV-associated diseases is the chronic fatigue syndrome without clearly 
defined underlying diseases (14-16). 
1.2 HISTORY 
At the end of the nineteenth century infectious mononucleosis was described almost 
simultaneously, by Filatov (17) and Pfeiffer (18) asan illness characterized by malaise, fever, 
hepatosplenomegaly, lymphadenopathy, and abdominal discomfort. The establishment of IM 
as a clinical entity is credited to Sprunt and Evans, who in 1921 described the synchronous 
symptoms of fever, lymphadenopathy, and prostration occurring in six previously healthy 
young adults (19). Two years later a more detailed morphologic description of the atypical 
lymphocyte was given by Downey and McKinlay (20). 
A major advance was made in 1932 when Paul and Bunnell, unexpectedly encountered high 
titers of spontaneous occurring sheep red blood cells agglutinins in the sera of patients with 
IM (21). The specificity of this test was later enhanced by Davidsohn by differential 
absorption of serum with a suspension of guinea pig kidney and with beef erythrocytes (22). 
EBV was detected in 1964 by Epstein, Achong and Barr (I). They described the presence of 
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Figure 1. Schematic representation of Epstein-Barr virus, 
consisting of 162 capsomers, surrounded by an envelope. 
particles, which resembled herpes viruses, in tissue cultures of biopsy specimens from 
patients with Burkitt's lymphoma. It was not possible to propagate the virus in conventional 
tissue culture systems. 
In 1966, an indirect immunofluorescence assay (IFA) for antibodies to EBV was developed 
by Gertrude and Werner Henle (23). High titers of these antibodies were detected in patients 
with Burkitt's lymphoma. Additional studies revealed that 90% of American adults had 
demonstrable EBV antibodies as well (23). The relation between IM and EBV was established 
in 1968 when one of the technicians in the Henle's laboratory, acquired IM and developed 
antibodies against EBV (24). With specific tests for EBV, it became apparent that about 10% 
of the cases of mononucleosis were caused by other agents, 5 to 7% by cytomegalovirus, 1% 
by Toxoplasma gondii, and, exceptionally by other viruses (3,25). 
1.3 DESCRIPTION OF EBV 
1.3.1 Taxonomy and structure 
EBV is one of the six herpes viruses which are known to cause human disease. The others are 
herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), varicella-zoster virus (VZV), 
cytomegalovirus (CMV) and human herpes virus type 6 (HHV-6). 
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The individual virions are 180 to 200 nm in diameter and appear as an icosahedral 
nucleocapsid consisting of 162 capsomeres, surrounded by a complex envelope (figure 1). The 
DNA of EBV is a linear, double stranded molecule of approximately 170 χ 10 nucleotide 
base pairs (26). In latently infected cells, most copies of the virus genome exist as a circular 
episome inside the nucleus (fig 2a) (27,28) and are replicated together with host cellular 
DNA. In these cells infectious virus particles are not produced. In replicative infected cells, 
infectious virus is actively produced and the viral DNA persists in a linear form (fig 2b,c) 
(28). The genome is interspaced by multiple internal repeat regions (IR) and flanked by 
desegregated terminal repeats (TR), at both ends (29). Covalent linkage between TRs at the 
ends of the DNA permits the episome to form (30). The largest tandem repeat region, (6-12 
repeats of a 3,071 bp sequence [IRl]), separates the genome into two major domains: a short 
unique region of 15,000 bp (Uj) and a long, largely unique region of 150,000 bp (U|) (fig 2b). 
TR TR 
IRl 
U2 
TR Ul IRl IIR2 U3 
I I I I I I I I I I I • 
IR3 U4 IR4 U5 TR 
1—1—I—ΙΓΤΤ I I I ι Ι Γ 
Figure 2. Schematic diagram of EBV DNA. 
a.) intracellular EBV DNA episome showing organisation of unique and major tandem repeal 
(R) DNA domains in relation to an EcoRI restriction endonuclease map of EBV DNA 
b.) linear virion showing long (U)) and short (Ug) unique region 
c.) linear virion showing organisation of unique (U) and major tandem repeat (R) DNA 
domains in relation to an EcoRI restriction endonuclease map of EBV DNA 
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Table 1. Major antigens induced by EBV infected cells. 
viral antigen abbreviation 
Epstein-Barr virus nuclear antigen EBNA 
Lymphocyte-detected membrane antigen LYDMA 
Early antigen EA 
restricted EA-R 
diffuse EA-D 
Membrane antigen MA 
Viral capsid antigen VGA 
Other direct repeats IR2, IR3 and IR4 further subdivide U| into the unique sequence domains 
U2, U3, U4 and U5. IR2 and IR4 are direct tandem repeats of sequences of 123 bp (8-12 
repeats) and 103 bp, respectively (figure 2c). The IR2 and IR4 repeats are widely separated 
in the genome but have a common origin (31). 
1.3.2 Biologic properties 
The host range of EBV is limited to man, its natural host, and some subhuman primates, 
including the gibbon, owl monkey, squirrel monkey and some species of tamarin, all of 
which can be infected experimentally. In vitro replication of the virus has been described 
only in B-lymphocytes of man (32), the owl monkey (Aotus) (33), and the cotton-top tamarin 
(Saguinus oedipus oedipus) (34). After infection by the virus, cells which contain the EBV 
genome are transformed. Transformation induced by EBV has to be confirmed by detection 
of the genome using cellular DNA hybridization with an EBV probe, or by the expression of 
Epstein-Barr nuclear antigen (EBNA) using anti-complement immunofluorescence techniques 
(ACIF). 
The cellular receptor for EBV corresponds to the C3d component of complement (CR2) 
(35,36). These receptors are present on nearly all B-lymphocytes of humans and certain 
nonhuman primates. They can also be demonstrated on a smaller proportion of complement 
receptor-bearing, non-B-, non-T-lymphocytes (37,38,39). After attachment to the receptor, 
the virus enters susceptible B-lymphocytes and EBV-related antigens are expressed. The 
major EBV-related antigens are shown in table 1. Following EBV infection, first EBNA and 
then cellular DNA and protein synthesis occur. EBNA is synthesized and expressed in nuclei 
of all infected cells within several hours after infection (fig 3) (40), and may be preceded or 
accompanied by the functional presence of lymphocyte-detected membrane antigen 
(LYDMA) (41,42). EBNA is used as an immunological marker for the presence of viral DNA. 
LYDMA presumably serves as a target for cytotoxic T-lymphocytes present in the circulation 
of EBV-infected individuals. Frequently, B-lymphocytes are latently infected and only 
express EBNA or LYDMA or both. In part of the cells, EBNA expression is followed by 
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Figure 3. A viral cycle consists of four stages. The first stage is the latent stage in which the 
viral DNA is in the episome form. The second stage is the early stage and could be induced by 
activaters such as TPA, anti-IgM, ludr or Budr. The third stage is DNA synthesis and can be 
blocked by inhibitors of DNA synthesis such as PAA, PFA, AraC, and acyclovir which inhibits 
expression of antigens of the late (fourth) stage. 
EBNA, Epstein-Barr nuclear antigen; LYDMA, lymphocyte detected membrane antigen; EA-D, 
diffuse form of early antigen; EA-R, restricted form of early antigen; MA, membrane 
antigen: VCA, viral capside antigen. 
early antigen (EA) expression (fig 3). The factors governing induction of latency or 
determining activation into the lytic cycle are unknown. The re-entry of latently infected 
cells into the lytic cycle may result in reactivation of the EBV infection. Entering the lytic 
cycle in vitro can be induced by activators such as butyrate sodium (BS), 12-0-tetradecanoyl-
phorbol-13-acetate (TPA), anti-immunoglobulin M (anti-IgM), 5-Iodo-2'-deoxyuridine 
(ludr) or 5'-bromodeoxyuridine (Budr) (31). Thereafter, viral DNA synthesis commences 
with the production of multiple copies of the EBV genome. Sporadically viral DNA may be 
incorporated into the DNA of the host cell, but mostly it remains in a circular non-integrated 
form as an episome. Linear integration of EBV-DNA into host cell DNA may be enhanced 
by stimulation of the host cells by B-cell mitogen such as bacterial lipopolysaccharide at the 
time of transformation (43). The tranformation of the host cell does not depend on the form 
of the DNA, integrated, episomal or the combination of the two forms (43). Inhibitors of 
DNA synthesis such as arabinofuranosylthymine (Ara-T), phosphonoacetic acid (PAA), 
phosphonophormic acid (PFA), and acyclovir block the appearance of the late stage (figure 3) 
(31). In the late stage, viral capsid antigen (VCA) and late membrane antigen (MA) are 
produced for the assembly and release of infectious virus particles (44). 
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Figure 4. Summary of the first steps in EBV transformation. For explanation see text. 
1.3.3 The virus antigens 
Several antigens have been described: Epstein-Barr nuclear antigens (EBNA), lymphocyte-
detected membrane antigens (LYDMA), membrane antigens (MA), the early antigen complex 
(EA), and the virus capsid antigens (VCA). 
1.3.3.1 Epstein-Barr nuclear antigen and other latent phase proteins 
All human cells transformed by EBV express EBNA, which generally cannot be demonstrated 
by direct or indirect immunofluorescence but only by indirect anti-complement 
immunofluorescence (45). It is first seen in small, resting lymphocytes at 8 to 24 hours after 
infection (p.i.) (figure 4). Subsequently the lymphocytes undergo blast transformation and 20 
h later they enter their first S-phase. EBNA synthesis precedes the cellular DNA synthesis 
during each cell cycle (46). It is an autonomous function of the viral genome, expressed 
independently of the viral or cellular controls, that limit the production of the other viral 
determined antigens (47). 
EBNA is now known to be a complex of proteins coded for by numerous genes: EBNA-l 
(48-53), EBNA-2 (54-56), EBNA-3a (57,58), EBNA-3b (59), EBNA-3c (60), EBNA-4 (61), 
EBNA-5 (=EBNA-LP) (62-64), and EBNA-6 (65). 
EBNA proteins are expressed from a single 68 kb RNA-transcript by an extremely complex 
pattern of splicing events (66). EBNA-l, the main EBNA component which is encoded by 
the Bam HI К fragment of the viral-genome, mediates episome-replication and maintenance 
through binding to the Ori-P repeat sequences within the Bam-C fragment. A second 
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function of the EBNA-1 protein is its capacity to act as a transcriptional enhancer of the 
latent promoter region located in close proximity to the Ori-P region (67,68). Thus, EBNA-1 
controls the level of expression of other EBNA proteins, including itself. EBNA-2, encoded 
by the Bam HI Y and H fragments, is the first protein to be expressed following EBV-
infection of B-lymphocytes in vitro (69) and is capable of strongly inducing CD23, an 
activation marker on B-cells (70). A soluble fragment of CD23 can act as an autocrine growth 
factor for B-cell growth, and is thus important in maintaining B-cell replication in the 
transformed state (71,72). The EBNA-2 protein has for long been the prime candidate EBV-
transforming protein since its coding region is deleted specifically in non-transforming 
strains of EBV, e.g. P3HR1 (73). Besides inducing CD23 expression, EBNA-2 strongly 
stimulates the expression of latent membrane protein (LMP) which has, more recently, been 
shown to be capable to induce growth transformation and oncogenesis in a rodent (cell)system 
(74,75). Thus EBNA-2 may stimulate EBV-transformation indirectly. 
EBNA-1 and 2 are stably expressed in mouse fibroblast or human lymphoid cells following 
transfection by DNA fragments containing the exons coding for EBNA-1 or EBNA-2. These 
transfected cultures are useful for the detection and titration of antibodies to these two 
components (76). IgG antibody to EBNA-1 appear long after IgG antibody to EBNA-2, 
increase gradually in titer, and in time exceed the level of EBNA-2 antibody. They then 
persist indefinitely, while antibody to EBNA-2 decline to low levels which persist or become 
non-detectable (76). EBV can be classified in type A and type В according to the 
organization of EBNA-2 (77) and EBNA-3 family of proteins (78). EBNA-2 exists as two 
antigenically different alleles, EBNA-2A and EBNA-2B, which share just 50% amino acid 
homology (77). Certain human sera from donors naturally infected with type 2A EBV-strains 
do detect the 3a, 3b and 3c proteins in any type of type 2A virus-transformed lymphocytic 
cell lines (LCLS) but detect only EBNA-3a in LCLS carrying type 2B isolates. Conversely, 
selected human sera from donors naturally infected with type 2B strains of EBV identified 
the EBNA-3a and two novel EBNAs of 160 and 180 kD. These novel proteins appear to be 
the type 2B homologs of EBNA-3b and -3c (78). 
Very little is known about the functions of the other EBNA proteins, except that EBNA-3 
appears to be an important target antigen for cytotoxic T-cell recognition (79a) and therefore 
might be a part of LYDMA. 
The latent membrane protein (LMP) has been widely studied and is also considered an 
important target for CTL-recognition (71). LMP is also capable of inducing morphological 
changes and immortal growth when transfected into rat and mouse cells. The transforming 
activity of LMP appears to reside in the N-terminal 30% of the protein, including the 
membrane spanning region (74,75). LMP is associated with small patches in the cell 
membrane and also with vimentin-filaments in the cytoplasm. Through this interaction LMP 
is thought to interfere with normal cell-cell communication and growth-control. LMP has an 
extremely short half-life of 30 minutes (71,73). 
Finally, very little is known about the recently described terminal protein (TP) (79b) which is 
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transcribed only after closure of the EBV-genome into the episomal form. Like LMP, TP 
appears to be transcribed into 2 messages, dependent on the status of the infected cell, i.e. 
latent versus replicative. However, no details are known about functional activities of the 
proteins derived from these alternative messages. 
1.3.3.2 Lymphocyte-detected membrane antigens 
Little is known about lymphocyte-detected membrane antigens (LYDMA). Their existence 
can be demonstrated by the T-cell-mediated killing reaction by human lymphocytes from a 
patient in the acute stage of IM. The antigens are expressed in EBV-transformed cells and 
not in EBV-negative cells. The T-cell response to LYDMA is HLA-restricted as are T-cell 
responses to other virus-induced antigens (80). In general, antibody detection has not been 
used successfully for demonstrating these antigens. 
1.3.3.3 The early antigen complex 
The early antigen complex (EA) is produced during the second phase in the replicative cycle. 
This production is preceded by a transition from the latent to the lytic state of EBV in the B-
cell. Little is known about this transition. However, thanks to the pioneering work of G. 
Miller and co-workers a genetic element was discovered in P^Rj-cells which was 
responsible for the relatively high level (5%) of spontaneous activation and virus-production 
in this cell line (81). This element consists of a rearranged fragment of EBV-DNA placing 
the Bam-Z fragment under control of the latent (Bam-W) promoter. 
Subsequent studies have led to the finding that in the normal EBV-genome the Bam-Z 
encoded protein is the first and most essential factor capable of inducing the lytic phase of 
EBV infection (82,83). 
The Bam-Z product (BZLFl) is capable of trans-activating the expression of a second set of 
EBV-proteins (BMLF1, BMRF1) (figure 5), encoded by the Bam-M and -R region which 
have broad trans-activating activities on the expression of both cellular and viral genes (84-
87). Thus, other viral genes are activated similarly to what is known in other members of the 
herpes virus family, i.e. the cascade regulation of gene expression. 
Essential for the induction of the second phase in the viral cycle are the Bam-Z, -M, and -R 
gene-products which are homologous to the so-called immediate-early-proteins. They 
activate the early-protein antigens. Next to activating the second-phase proteins (early 
antigens) the Bam-Z gene products down-regulate the expression of EBNA-proteins (figure 
5) (88). 
The Bam-Z encoded protein can be induced by chemical treatment using TPA or butyrate or 
by membrane signalling using anti-IgM. These are widely used procedures to induce EBV 
expression in latently infected cell lines (figure 3 and 5). 
The second phase in the replicative cycle is characterized by the production of the EA-
complex and of a variety of virus-encoded enzymes involved in the nucleotide metabolism of 
the host cell. Examples are thymidine-kinase, ribonucleotide reductase, and the important 
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Figure 5. Schematic presentation of the trans-activating open reading frames leading to virus 
replication. 
viral DNA-polymerase. Inhibition of DNA-polymerase using PFA, BUDR or acyclovir 
blocks transition to the final stage of replication, i.e. expression of structural proteins (figure 
3). 
The EA complex can be subdivided into two components of which one designated "restricted" 
(R), is confined to the cytoplasm while the other, "diffuse" (D) can be found both in nuclei 
and cytoplasm (89). The EA(R) antigen is destroyed by 95% methanol while the EA(D) 
antigen is not. Both are preserved after acetone treatment but EA(D) is more sensitive to 
proteolytic enzymes than the EA(R) antigen (89). EA(D) appears before EA(R) in the early 
stage of the viral replication cycle. 
Sera from acute IM patients contain anti-EA(D) antibody more frequently than anti-EA(R) 
(90). In contrast, sera from patients with BL contain anti-EA(R) or anti-EA(R) and anti-
EA(D) more frequently than anti-EA(D) alone (91). Sera from patients with NPC often 
contain both antibodies, with anti-EA(D) usually being predominant (92). 
The appearance of EA is the first definite sign that the cell has entered into the lytic cycle 
(93,94). All VCA positive cells also contain EA but VCA negative and EA positive cells can 
be seen when DNA synthesis is inhibited (94-96). Production of EA is not dependent on 
EBV-DNA synthesis. EA is classified as a nonstructural antigen complex (97). 
Two polypeptides within this EA-complex, 138,000 dalton and 45,000-51,000 dalton 
respectively, appear to be good candidates for diagnostic purposes in infectious 
mononucleosis (98). 
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1.3.3.4 The viral capsid antigen 
The viral capsid antigen (VGA) was the first antigen that was detected by indirect 
immunofluorescence (23). The VCA-immunofluorescence test detects antibodies directed 
against antigens expressed on intracellular membranous structures as well as those associated 
with the viral capsid (99,100). 
The major polypeptides composing the VGA complex have now been identified. Monoclonal 
antibodies have been produced against polypeptides with a molecular weight of 125,000 
dalton and 160,000 dalton. These polypeptides have now been purified and partially 
characterized (101,102,103). The 160,000 dalton protein is non-glycosylated and located 
mainly in the nuclei of infected cells (103). The 125,000 dalton protein is glycosylated and 
located both in the cytoplasm and nuclei of virus-producing cells (102). All human sera from 
EBV-infected individuals that have been tested to date, reacted with the 125,000 dalton 
glycoprotein and most but not all sera from EBV-infected individuals also reacted with the 
160,000 dalton protein (103). Exceptions have generally been sera collected during the acute 
phase of IM. This suggests that the 125,000 dalton protein appears to be the major 
immunogen following primary infection with EBV. 
A VGA-marker protein of 18,000 dalton reacts with most, if not all, sera from healthy 
seropositive blood donors (98) and can be prepared on a large scale. Therefore, it is likely to 
represent an important antigen for determination of seropositivity i.e. latent EBV infection. 
1.3.3.5 Membrane antigens 
Membrane antigens (MA) are expressed in the membranes of viable lymphoblastoid cells 
supporting the replication of virus particles and comprises at least three different antigenic 
specificities (gp 300/350, gp 200/250 and gp 85/90)(104). It is also expressed on the 
envelopes of mature virus particles and is responsible for the induction of neutralizing 
antibodies (105,106). This established the basis for the development of a subviral MA vaccine 
(see 1.8.2). 
1.4 EPIDEMIOLOGY 
EBV has a world-wide distribution. In general, infection is acquired earlier in life in 
economically less developed than in industrialized countries. Over 90% of adults in most 
populations have demonstrable EBV antibodies (107,108). EBV seroconversion usually occurs 
either before the age of 5, or early in adolescence. In children, disease is rarely apparent but 
it is diagnosed most frequently among adolescents in industrialized countries in the form of 
IM (109). The incidence in the United States of America was highest in the 15- to 24-year 
age group and was similar in both sexes (110). Peak incidence occurred 2 years earlier in 
woman. No clear seasonal incidence has been noted. 
EBV is transmitted mainly via saliva. Among young adults spread of the virus may be 
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facilitated by transfer of saliva with kissing (111,112), hence the name "kissing disease". The 
virus may also be spread among susceptible siblings within families (113). Only 6% of those 
with IM cite previous contact with another affected individual (114). EBV is transferred 
rarely by blood transfusion (115,116) or bone marrow graft (117). The virus can be cultured 
from throat washings of around 15 to 75% of healthy EBV-seropositive adults depending on 
the sensitivity of the assay used (118). In immunosuppressed persons, viral shedding is very 
common (119-121). The virus can also be spontaneously isolated from the peripheral 
lymphocytes in 8% of healthy adults (122). Addition of cyclosporin A increases the isolation 
rate to approximately 75% of the samples (118). Virus has not been recovered from 
environmental sources. These data suggest that EBV is not very contagious. Although it is 
widely present in the community it is only spread by intimate contact between virus 
excreting and susceptible individuals. 
1.5 PATHOGENESIS 
1.5.1 Histopathologic findings 
During the acute phase of IM, lymph nodes throughout the body are moderately enlarged and 
individual nodes reveal increased numbers of enlarged, moderately-active lymphoid-
follicles. Germinal centers are also enlarged with cores containing blast cells, histiocytes, and 
lymphocytes. Though the reticulin framework remains intact, invasion by the hyperplastic 
pulp makes its borders less distinct (123). The spleen is usually two to three times its normal 
weight (124). This is mostly the result of hyperplasia of the red pulp. Tonsillar biopsy 
specimens obtained during the course of IM reveal intense proliferation of numerous mitoses 
(125). Bone marrow aspirate and biopsy specimens are normal in contrast to the peripheral 
blood. Changes in hepatic histology are usually mild and hepatocytes show minimal swelling 
and vacuolization. Bile ducts may be minimally swollen, but frank biliary stasis is rare (126). 
In fatal cases of IM histopathologic changes in the central nervous system have been 
described (125,127). 
1.5.2 Humoral- and cell-mediated immunoresponses 
The likely route of initial EBV infection is via the oropharynx. EBV-DNA has been detected 
in oropharyngeal epithelial cells and the virus presumably infects susceptible B-lymphocytes 
within lymphoid tissue of the pharynx either simultaneously or subsequently (128). During 
the 30-50 day incubation period, replication and dissemination of the virus occurs throughout 
the lymphoreticular system. Both humoral- and cell-mediated immune mechanisms are 
involved in the control of EBV infection. 
Antibodies directed against viral antigens, as well as against unrelated antigens (heterophile 
antibodies) found on sheep-, horse- (agglutinins) and beef-red-cells (hemolysin) are 
produced. The role of the heterophile antibodies is unclear. They are a group of 
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predominantly IgM antibodies and do not cross-react with antigens specific for EBV (129). 
There is no good correlation between the heterophile antibody titers and the severity of the 
illness. 
A recent primary EBV infection is defined serologically by the early appearance of 
circulating anti-VCA immunoglobulin M (IgM) antibody and their subsequent decrease to 
non-detectable levels (1.7.3, fig 6). Almost at the same time increasing amounts of anti-VCA 
IgG antibody appears and persist for life in normal persons. Anti-EA(D) IgG antibody are 
produced transiently in about 80% of infected individuals. IgG antibody to EA(R) are rarely 
present in the acuta phase, but may appear transiently during late convalescence. IgG 
antibody to EBNA are usually absent during acute infection but are detected weeks to 
months later and also persist for life. Immunocompromised individuals demonstrate either 
unusually low or high antibody titers to EBV-specific antigens. In these patients a lack of 
antibodies to EBNA is often observed (11,130). 
The first line of defense against EBV infection comes from the interferon excreted by the 
viral infected B-cells and the T-cells responding to viral infection (130,131). Interferon may 
control EBV-induced B-cell lymphoproliferation by antiviral replication activity, 
antilymphocytic proliferative response, and boosting of natural killer (NK.) cell activity 
(130,132). Interferon and NK-cells may act synergistically to protect against the virus. 
However EBV-specific cytotoxic T-cells are considered to be the most important factor in 
controlling B-cell proliferation. The majority of the atypical lymphocytes found in the 
peripheral blood during IM are suppressor T-cells (133). 
1.6 CLINICAL MANIFESTATIONS 
The age of the patient has a profound influence on the clinical manifestation of a primary 
infection. Primary infection in children is often asymptomatic. In almost all adult patients 
with primary infection IM is a self-limiting illness lasting several weeks or months. In rare 
cases serious disease occurs accompanied by severe prostration, major complications, and 
even death. 
1.6.1 Symptoms 
In the vast majority of cases, the triad of sore throat, fever, and lymphadenopathy comprises 
the clinical picture (134,135). The onset may be abrupt, but often several days of prodromal 
symptomatology is observed, including chills, sweating, fever, anorexia, and malaise. 
Headache, myalgia, and a sensation of abdominal fullness are other common prodromal 
symptoms. Rarely the first manifestation of illness is one of the complications of IM 
described below. 
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1.6.2 Signs 
The three most frequent signs are lymphadenopathy, pharyngitis and fever (134,135,136,137). 
Cervical adenopathy is present in 80% to 90% of the patients. Posterior nodes are most 
commonly involved but submandibular and anterior adenopathy are also quite frequent. 
Axillary and inguinal adenopathy may also occur. Tonsillar enlargement is usually present 
and the pharynx is erythematous with an exudate in about one-third of the cases. Palatal 
petechiae may be seen in 25% to 60% of the cases, but are not diagnostic of IM. 
Fever is present in over 80% of patients and usually peaks in the afternoon with temperatures 
of 38-39^ resolving over a 10- to 14-day period. A rash is present in about 5% of the 
patients and may occur after administration of ampicillin (138,139). Periorbital edema has 
been reported in up to one-third of the cases in some series (134), but it has been less 
frequently observed in others. The lungs and heart are usually normal and neurological signs 
are generally absent but hepatomegaly is present in 10% to 15% and jaundice in 
approximately 5% of cases (134). Careful examination shows that splenomegaly occurs in 
about one-half of the cases during the course of the illness. 
1.6.3 Complications 
Most patients recover uneventfully. Complications generally resolve fully, although there 
have been fatalities (140). 
Autoimmune hemolytic anemia occurs in 0.5 to 3.0% of the patients and subsides after a 1-
to 2-months period. 
Mild thrombocytopenia is common but profound thrombocytopenia with bleeding occurs 
rarely (141), although platelet counts below 1000/mm and deaths from intracerebral bleeding 
have been reported (140,143). Cold agglutinins are present in 70% to 80% of the cases (144). 
Splenic rupture is a rare but dramatic complication and its incidence is highest in the second 
or third week of the illness. Abdominal pain is uncommon in IM and splenic rupture must be 
strongly considered whenever this occurs (145). A history of trauma is obtained in about one-
half of the patients with splenic rupture (146), therefore, exclusion of contact sports and 
caution during splenic palpation are prudent measures in the first few weeks after diagnosis. 
Neurologic complications, which occur in less than one percent of the cases can, on occasion, 
be the first or only manifestation of IM. Encephalitis may be acute, rapidly progressive and 
severe but there is usually complete recovery. Low titers of EBV-VCA can be found in the 
cerebrospinal fluid (147). Cases of Guillain-Barré syndrome, Bell's palsy, and transverse 
myelitis have been reported in primary EBV infection (148). Eighty-five percent of the 
patients with neurologic complications recover completely (149). 
Hepatic manifestations consist largely of self-limited elevations of hepatocellular enzymes 
and are present in over 80% of the cases. 
Cardiac disease and pulmonary manifestations are very uncommon (150). 
Death is a rare outcome (151,152) but may occur either as a result of overwhelming infection 
or from complications of the disease. 
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1.6.4 EBV-associated diseases 
1.6.4.1 Burkitt's lymphoma 
Burkitt's lymphoma (BL) is a non-Hodgkin lymphoma. It belongs to the high-grade, 
malignant lymphoma, small non-cleaved cell group (153). Geographically, the disease is 
distributed in equatorial Africa and New Guinea where holoendemic malaria occurs (154). 
The incidence is about 10 per 100,000 at risk per year. More than 95% of cases are EBV 
genome positive (155). The reason for the malignant course of EBV infection in these regions 
is not known, but appears to be due to a decreased immune control of the EBV infection. 
The depressed T-cell-mediated immune control of EBV infection might be caused by 
activation of suppressor T-cells by malaria (154,156,157). Moreover, continuous antigenic 
stimulation of EBV-infected B-lymphocytes by malarial antigens may promote development 
of BL (154). However, another report has shown that malaria does not seem to influence the 
immunological response to EBV infection, as measured by antibody titers to VGA (158). 
Patients show elevated IgG-VCA antibody titer before the onset of symptoms (108). Around 
75% of patients exhibit IgG antibody against EA-R and there is a direct relationship between 
the level of the VGA antibody titers and those of the EA response (159). 
1.6.4.2 Nasopharyngeal carcinoma 
Genetic and certain cultural patterns predispose to the development of nasopharyngeal 
carcinoma (NPC), which is the most prevalent tumor in males living in southeast China. 
Eating salted fish containing appreciable quantities of nitrosodimethylamines and other 
environmental factors seem to be critical risk-factors in the development of NPC (160,161). 
EBV-DNA sequences and EBV-induced EBNA have been detected in epithelial cells (162-
164). Elevated IgG and IgA antibody levels against VCA and EA-D are found in NPC 
patients. The detection of IgA antibody against VCA is useful in establishing the diagnosis 
and prognosis of NPC(165,166). 
1.6.4.3 Chronic mononucleosis syndrome 
Several groups have described a protracted illness usually preceded by IM, with persistent 
fatigue, headache, myalgia, lymphadenopathy, and low-grade fever (4,14-16,167,168). Many 
of the patients had EBV antibody profiles suggestive of a chronic EBV infection (14-16,167). 
However, in a recent study, EBV was shown not to be related to an endemic form of chronic 
mononucleosis-like disease with the apparent lack of correlation between EBV antibody titers 
and the presence of chronic fatigue symptoms (169). 
It is proposed that "chronic mononucleosis" is a syndrome that persists for many months and 
years following typical heterophile-positive, acute IM with serologic evidence of primary 
EBV infection (168). 
Patients with the chronic mononucleosis syndrome produce extremely high IgG antibody 
titers to VCA and EA-D, while antibody to EBNA remain at normal or subnormal levels 
(170). They tend to experience pancytopenia and polyclonal hyper-gammaglobulinemia. The 
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EBV genome has been detected in lymphoproliferations from these patients (171). 
Furthermore, a defective non-transforming strain of EBV was isolated from a child with this 
syndrome, suggesting that the generation of virus strains with atypical genome may be a 
common phenomenon in certain patients (172). The patterns of EBV-specific antibodies and 
the presence of the EBV genome in tissues strongly suggest that these patients have a subtle 
immunodeficiency specific for EBV (173). 
1.6. S EBV-induced disorders in immiuiodeficient patients 
1.6.5.1 X-linked lymphoproliferative syndrome 
Patients with the X-linked lymphoproliferative syndrome (XLP) fail to control B- and T-cell 
lymphoproliferative responses to EBV, especially by cytotoxic-T-, NK-, and suppressor-T-
cells. As a result two-thirds of the males with XLP succumb to severe or fatal IM. 
Immunohistochemical studies of lesions in the liver and bone marrow reveal EBV-carrying 
B-cells mixed with suppressor T-cells and fewer numbers of NK-cells (5,174,175). These 
uncontrolled lymphoid cells produce lesions in the tissues, resulting in fulminant hepatitis or 
in the virus-associated hemophagocytic syndrome in bone marrow (140). 
Recent studies have demonstrated that the syndrome is due to a mutation in the X-
chromosome and may be detected by a specific probe (9). Therefore, it is possible to screen 
prenatally members of a family with XLP for this mutation. 
1.6.5.2 Primary immunodeficiencies 
Patients with primary immunodeficiencies have defective responses to EBV, often associated 
with increased levels of IgG antibody to VGA and EA-D, but with low or non-detectable 
antibody levels to EBNA (5,176-178). Recently, EBV-carrying lymphoproliferative disease 
has been documented in patients with ataxia-telangiectasia (AT) (178,179). The 
immunodeficiency in AT is a combined T- and B-cell process which is progressive (178). 
Other patients with primary immunodeficiency disorders, such as the Wiskott-Aldrich 
syndrome, and with severe combined immunodeficiency syndrome, common variable 
immunodeficiency, post-thymic epithelium transplantation and individuals with Chediak-
Higashi syndrome develop EBV-induced lymphoproliferative diseases (117,180,181,182). 
1.6.5.3 Organ transplant patients 
EBV causes an increase in lymphoproliferative diseases in recipients of renal, cardiac, lung, 
liver, bone marrow, and thymic epithelium transplants (12,117,182,183). It has been 
postulated that the increased incidence might be due to impaired immunosurveillance, 
chronic antigenic stimulation from the allograft, or direct oncogenic effects of 
immunosuppressive drugs (12). In general, immunosuppressive drugs used to prevent organ 
allograft rejection suppress immunity, particularly T-cell mediated, and predispose the 
individual to all herpesvirus infections. Defective immunosurveillance seems to allow B-cell 
proliferation to persist due to EBV infection. The degree of immunosuppression rather than 
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the particular type of immunosuppressive agent is probably the most important predisposing 
factor. 
1.6.5.4 AIDS 
There is an increasing number of reports that EBV is associated with the development of 
four lesions found in AIDS patients: (i) hairy leukoplakia (13,184); (ii) lymphadenopathy 
(185); (iii) malignant lymphoma (186,187); and (iv) lymphoid interstitial pneumonitis (188). 
Furthermore, human immunodeficiency virus (HIV) and EBV have been shown to co-infect 
B-cells (189). Patients frequently show elevated IgG antibody titers to VCA and EA-R (190) 
possibly by loss of control of latent EBV due to HIV infection (191). Another possibility is a 
cellular interaction between EBV and HIV (190,192,193). 
1.6.5.5 Miscellaneous 
Other diseases associated to EBV are rare lymphomas e.g. some T-cell lymphomas (194,195), 
thymic carcinoma (196), and involvement of the thyroid gland (197). Hodgkin's disease may 
in some patients be preceded by enhanced activation of EBV (198). EBNA and rheumatoid 
arthritis nuclear antigen may be related (199,200). 
1.7 LABORATORY DIAGNOSIS 
1.7.1 Hematologic findings 
The most common hematologic manifestation of the illness is a relative and absolute 
mononuclear lymphocytosis which occurs in about 70% of the cases. White cell counts can 
vary from 12 to 50,000 leukocytes/mm . Atypical lymphocytes are the hematologic hallmark 
of IM, and can account for about 30% of the differential count at the height of the atypical 
lymphocytosis (136). A relative and absolute neutropenia is evident in 60 to 90% of the cases 
and is usually mild. (201-204). Thrombocytopenia is also common. 
1.7.2 Heterophile antibodies 
The Paul-Bunnell-Davidsohn test detects heterophile antibodies of the IgM class that have 
the ability to agglutinate sheep, horse, goat and camel erythrocytes (21). They are further 
differentiated from heterophile antibodies associated with other diseases by their significant 
absorption to beef erythrocytes but not to a suspension of guinea pig kidney (205). The 
differential absorption with a suspension of guinea pig kidney permits distinction between 
the naturally occurring Forssman antibodies, the antibodies of serum sickness, and 
heterophile antibodies of IM. A titer of 40 or higher after absorption in combination with a 
compatible clinical presentation is strongly suggestive of IM. 
Heterophile antibodies are present at the onset of illness or may appear shortly afterwards in 
about 90% of adult patients. Infections by cytomegalovirus, hepatitis viruses, rubella virus, 
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herpes simplex virus, adenovirus, and Toxoplasma gondii may also cause mononucleosis, but 
these infections can be differentiated from IM by testing for specific antibodies. Also these 
patients rarely exhibit a positive heterophile antibody test (25,144). 
1.7.3 EBV-specific antibodies 
The interpretation of serological tests is based on the profile of antibody titers against a panel 
of three antigens: VCA, EA and EBNA (figure 6). 
Antibodies to VCA arise early in the course of the illness and are demonstrable at 
presentation in almost all patients. Most of the symptomatic patients show near-peak 
antibody titers of IgG-, IgM- and IgA-VCA soon after onset of symptoms. A fourfold rise in 
IgG-VCA can be demonstrated in only 10-20% of the cases. IgG-VCA persist for life and 
can be used to indicate immunity, whereas IgM-VCA is transiently present and is specific for 
the acute phase. In general, IgM-VCA disappears within 1 to б months after the onset of 
infection. The presence of IgM-rheumatoid factor can result in a false-positive IgM reaction 
in indirect assays for IgM-VCA (206). 
Figure 6. Evolution of EBV antibodies during a primary infection. For explanation see text. 
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Antibodies against EA (anti-EA) are detectable in about 80% of the patients with IM. They 
arise later in the course of the illness than antibodies to VCA and disappear in most cases 
after recovery. Antibodies to EBNA (anti-EBNA) appear late in most cases and persist for 
life (90). The appearance of anti-EBNA in a patient who was previously IgG-VCA positive 
and anti-EBNA negative, is strong evidence of recent EBV infection. The antibodies to 
VCA, and EA are usually measured by the indirect immunofluorescence assay, anti-EBNA 
must be measured by the anticomplement-immunofluorescence method (ACIF) (5,11,45,207). 
Recently, enzyme-linked immunosorbent assays (ELISA) have been developed to detect 
antibodies specific for EBV-related antigens (208,209,210). 
1.7.4 Detection of the virus 
To demonstrate the presence of the virus genome in human tissues, the genome is detected by 
nucleic acid hybridization (211) or by the presence of EBNA by ACIF (45). These techniques 
can be performed either by direct staining or after in vitro cultivation of samples on cord 
blood lymphocytes. They can also be used for detection of the virus in peripheral blood 
lymphocytes, lymphoid cells from lymphoproliferative lesions, and throat washings 
(5,212,213). 
1.8 TREATMENT AND VACCINATION 
1.8.1 Treatment 
Treatment of IM is largely supportive since more than 95% of the patients recover 
uneventfully. The patients level of activity is generally slowed down to what the individual 
patient is able to perform, contact sports should be avoided. Corticosteroids are sometimes 
advocated, but their use is still controversial. The role of antiviral therapy is still unclear. 
Phosphonoacetic acid (PAA), adenine arabinoside (Ara-A), acyclovir, and interferon have 
been shown to inhibit EBV in vitro (95,96). Interruption of virus shedding in the throat was 
observed in a small number of patients with IM treated with intravenous acyclovir but there 
was little clinical effect (214). 
1.8.2 Vaccination 
Because of the implication of EBV, along with other factors, in the induction of NPC, BL 
and some lymphoproliferative disorders, studies were undertaken for development of a 
vaccine (215). A 340,000 dalton glycoprotein (gp 340), the virus-determined membrane 
antigen, expressed on the surface of EBV-infected cells, was chosen as the antigen for 
immunization. Tamarins were immunized either with the gp 340 antigen incorporated in 
liposomes (216) or with vaccinia virus in which the gp 340 genome had been cloned (217). 
Protective Immunity was achieved by both vaccines. However, there are expected serious 
problems with using these preparations in man (218). Therefore, gp 340 was administered 
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with an adjuvant of muramyl peptidase and this combination now has to be evaluated in man 
(218). 
1.9 AIM OF THE STUDY 
Development and evaluation of serological and virological techniques for EBV detection and 
their application in the diagnosis of EBV infections are subjects of study in this thesis. 
Current knowledge about the virus is described in chapter 1. 
In chapter 2 the optimization of the assay for isolation of the virus with respect to sensitivity, 
rapidity and standardization is presented. The results of this work are applied in chapter 3 in 
a study of the transfer of EBV in bone marrow transplantation. Beside the isolation of the 
virus in the stem cell fraction of bone marrow, spontaneous outgrowth of peripheral 
lymphocytes, excretion of EBV in the throat and detection of antibodies to EBV are 
investigated as markers indicating presence of the vims. Another application is presented in 
chapter 4 in order to assess the significance of serological markers and virus excretion from 
throat washings in patients with an active EBV infection. A comparison of IM patients in 
relation to patients without serological evidence of a recent infection and healthy individuals 
is made. 
The results of this study are used to evaluate in chapter 5 the need for various diagnostic 
laboratory assays, both specific and general, in confirming recent EBV infection in patients 
with complaints suggestive for a primary infection in a general practice. 
In chapter 6 we investigated the antibody prevalence for EBV in people from 0 to 65 years 
and compared the results with those for antibodies to the other human herpesviruses in the 
same samples and to literature. 
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CHAPTER 2 
DETECnON OF INFECTIOUS EPSTEIN-BARR VIRUS: USE OF VARIOUS 
CELL SYSTEMS AND DETECTION METHODS ' 
2.1 SUMMARY 
To develop a more sensitive, rapid and better standardized assay for infectious Epstein-Barr 
virus (EBV) we examined the susceptibility of lymphocytes from cord blood (LCB) and from 
adult EBV-seronegative donors (LAD) as well as BJAB cells. Using cell transformation as the 
criterion for EBV infection, the virus titer of a standard inoculum varied between 1.5 and 7.5 
'WrCIDstf'ml for LCB and between 2.3 and 6.5 1ClogTCID5(/ml for LAD. When the 
presence of Epstein-Barr nuclear antigen (EBNA) was used as criterion for EBV infection, 
virus titers ranged between 2.5 and 9.5 'nogTCIDsg'ml for LCB, between 4.0 and 9.5 
^ogTCIDst/ml for LAD and were maximal 3.5 ^ogTCIDso'ml in BJAB cells. Analysis of 
the standard inoculum for the amount of EBV using DNA hybridization with a biotin-labeled 
probe showed that the sensitivity of the DNA hybridization was equivalent with a titer of 2.5 
'MogTCIDsi/ml in cell transformation. Infectious EBV was detected by EBNA 5 days earlier 
than by cell transformation, maximum titer being reached two weeks after inoculation. LAD 
from a selected donor yielded a titer of 9 ± 0.5 ^logTCIDjQ^ml in samples obtained at 
bimonthly intervals. 
Lymphocytes from selected cord blood as well as those from selected seronegative donors can 
be used to detect infectious EBV. However, LAD offer the possibility of a regular supply of 
cells affording better standardization. 
G. Weers-Pothoff, H.P. Janssen, A.M. van Loon. Presented at the Third International 
Symposium on Epstein-Barr Virus and Associated Malignant Diseases, Rome, 1988. 
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2.2 INTRODUCnON 
Infections with the Epstein-Barr virus (EBV) are widespread in the community and are 
generally acquired during childhood having a subclinical course. However, infection during 
adolescence causes infectious mononucleosis in more than 50% of the infected persons (1). 
Furthermore, as in other herpes infections, chronic infection has been reported. Different 
manifestations of chronic EBV infections have been described (2,3) and the virus has been 
suggested as a cause of the chronic fatigue syndrome (4-7). The diagnosis of chronic 
infection has been severely hampered by the lack of suitable diagnostic parameters to 
establish the presence of ал active EBV infection. Some investigators have suggested that the 
amount of EBV excretion in the throat might be a suitable diagnostic criterion of chronic 
infection (7,8). Isolation of EBV is also important for studying antigenic and genomic 
variability (9), as for example in Epstein-Barr nuclear antigen typing (EBNotyping) (10). 
The presence of infectious EBV can be detected by a cell transformation assay using cord 
blood lymphocytes (LCB) (11). However, this requires 6 to 8 weeks before a final result is 
obtained (12). Moreover, the sensitivity of cord blood lymphocytes to infection with EBV is 
quite variable (12,13). 
We investigated EBV-negative lymphoblastoid cells (BJAB) (14) and lymphocytes from adult 
EBV-seronegative donors (LAD) for their suitability in detecting infectious EBV. A standard 
inoculum of the B95-8 strain of EBV was used as source of infectious virus. EBV infection 
was detected microscopically for signs of lymphocyte transformation (12) and by means of 
Epstein-Barr nuclear antigen (EBNA) detection using anticomplement-immunofluorescence 
(15) until 8 weeks after inoculation. In addition, we examined the sensitivity of a dot-spot 
DNA hybridization. 
2.3 MATERIALS AND METHODS 
2.3.1 Cells and virus 
Cord blood from ten placentae and venous blood from three, EBV-seronegative adult donors 
was collected in heparin. Mononuclear cells (MNC) were isolated by buoyant density 
centrifugation on Ficoll-Paque (Pharmacia) using standard procedures. The MNC were 
stored in liquid nitrogen until use. After thawing, the cells were washed with RPMI-1640 
(Gibco) and suspended at a concentration of 2.10 cells/ml in growth medium consisting of 
RPMI-1640 with 10% fetal calf serum, 100 U/ml penicillin, 50 pg/ml gentamicin, 100 
Ug/ml vancomycin and 2.5 pg/ml amphotericin B. The BJAB cells and the B95-8 cells were 
grown in the same medium without vancomycin and amphotericin B. To prepare a standard 
inoculum with infectious EBV, B95-8 cells at 5.10 cells/ml were subjected to freezing and 
thawing three times. After centrifugation at lOOOxg for 10 minutes the supernatant was used 
as standard inoculum. Aliquots of 4 ml were stored at - 7 0 ^ and were used for all 
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experiments. 
2.3.2 Cell culture and inoculation 
Aliquots of 100 μΐ containing 2 x 1 0 cells/ml in growth medium were placed in wells of a 
96 well microtitration plate (Costar 3595). The cells were inoculated at least in duplicate with 
150 μΐ of the B95-8 stock virus in a series of tenfold dilutions ( 1 0 _ 1 - 10 7 and the plates 
were incubated at 36 С in an atmosphere of 5% CO2. One third of the growth medium was 
replaced twice weekly. In addition, BJAB cells were diluted 1 in 2 once weekly. The 
microtitration plates were examined for transformation at least once weekly during 5 weeks. 
2.3.3 Epstein-Barr nuclear antigen detection 
After microscopic examination for cell transformation, all cells from each well were divided 
over five preparations and were fixed with acetone-methanol. EBNA was detected by the 
anti-complement immunofluorescence assay (15) using FITC-conjugated goat anti-guinea pig 
C3c (GAGp/СЗс, Nordic). A culture was considered positive when at least one EBNA 
positive cell was detected in two or more of the five preparations. 
2.3.4 DNA extraction and hybridization 
For DNA hybridization 150 yl samples of each of the desired EBV dilutions of the standard 
inoculum were incubated with 50 ug/ml proteinase К (Boehringer Mannheim) in 10 m M 
Tris-HCl (pH=7.8), 5 mM EDTA and 0.5% sodium dodecyl sulphate (SDS) for one hour at 
Л°С. After incubation, the samples were extracted twice with redistilled phenol, saturated 
with a buffer of 10 mM Tris-HCl (pH=7.4) and 1 mM EDTA, and twice with chloroform-
isoamyl alcohol (24:1). The DNA fractions were denatured by heating at 1 0 0 ^ for 10 
minutes. The samples were cooled directly in an ice-water bath for 5 minutes and applied 
under vacuum to a nylon filter (Amersham) by use of a 96 well manifold (Bethesda Research 
Labs). The DNA was linked to the nylon filter by UV irradiation for 4 minutes. 
Hybridization with 200 ng/ml of a biotin-labeled EBV-Bam HI "V" probe (Enzo Biochem. 
Inc.) was carried out for 18 hours at 4 2 ( t as previously described (16). After hybridization 
the filter was washed under stringent conditions (16) and was blocked with 1% non-fat milk 
powder and 4% normal rabbit serum in phosphate-buffered saline (PBS) for 10 minutes at 
room temperature. Thereafter 22 U/ml alkaline phosphatase-labeled streptavidin (Bethesda 
Research Labs) in blocking buffer was added to the mixture and the filter was incubated for 
30 minutes at room temperature, then washed three times with 0.01 M PBS at pH=7.2 
containing 0.05% Tween 20. After washing, it was developed with 250 yg/ml 3-bromo-4-
chloro-3-indolyl phosphate and 100 pg/ml nitro blue tetrazolium in a buffer of 0.1 M Tris-
HCl (pH=9.5), 0.1 M NaCl and 5 mM MgCl2 for one hour at room temperature. The reaction 
was stopped by washing the filter with distilled water. 
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2.4 RESULTS 
2.4.1 Time course of EBV infection 
Transformation of cord blood lymphocytes was observed for the first time 7 days after 
infection with the standard EBV inoculum (figure 1). A maximum titer of 4.7 
4ogTCID5(j'ml was reached at day 35. The first cultures were positive by EBNA detection 
two days after inoculation and reached a maximum titer of 6.5 iogTClD5(/ml 10 days after 
infection. Successive experiments were terminated at 5 weeks after inoculation. 
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Figure 1. EBV infection of cord blood cells after inoculation with a tenfold dilution series of 
the standard inoculum. EBV infection was determined microscopically or by EBNA detection. 
2.4.2 Comparative susceptibility of various cells after infection with EBV. 
The virus titer determined by means of cell transformation of cord blood lymphocytes and of 
lymphocytes from EBV-seronegative donors ranged from 1.5 to 7.5 4ogTCID5gr'ml and from 
2.3 to 6.5 'HogTCIDji/ml, respectively (table 1 and 2). BJAB cells could not be examined by 
microscopy for signs of transformation because they showed spontaneous clumping since they 
are already transformed. The titers obtained by EBNA detection ranged from 2.5 to 9.5 
"ogTCIDsQi'ml for cord blood lymphocytes, from 4.0 to 9.5 'logTCIDsj/ml for lymphocytes 
from seronegative donors and from 2.5 to 3.5 iogTCID5(/ml for BJAB cells. The maximum 
titers by EBNA detection were reached in all cell types 14 days after inoculation. In contrast, 
maximum titers bij transformation assay were found between 3 and 5 weeks after 
inoculation. The maximum EBNA titer was reached about one week earlier in cord blood 
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Table I. Comparison of virus titers of the standard EBV Inoculum assayed in cord blood 
lymphocytes, lymphocytes from adult EBV-seronegative donors, and В JAB cells. Infection was 
determined by cell transformation or EBNA detection at 3 weeks after inoculation. 
Virus titers of standard inoculum ( nog TCIDsg'ml) 
cell transformation EBNA detection Cells 
cord blood 
Experiment 
number 
1. 
2 
3 
4 
5 
б 
7 
8 
9 
10 
4.4 
8.0 
7.5 
2.0 
1.5 
5.0 
3.5 
3.5 
3.5 
2.5 
6.5 
3.5 
8.0 
8.0 
3.5 
5.5 
5.5 
9.5 
3.5 
2.5 
lymphocytes 
EBV-seroneg­
ative donor 
BJAB cells 
T« 
J 
E 
1 
2 
2.3 
3.2 
3.0 
NA* 
NA 
8.5 
4.5 
4.0 
3.5 
2.5 
control showed spontaneous clumping but was EBNA negative 
different donors 
vims titer not available due to spontaneous clumping of cells 
Table 2. Reproducibility of the virus titration of the standard EBV inoculum in adult EBV-
seronegative lymphocytes collected with 2 months intervals. EBV infection was determined at 3 
weeks after inoculation by transformation and EBNA detection. 
Adult EBV-seroneg­
ative donors 
donor Τ 
donor J 
donor E 
Virus títere of standard inoculum (nog 
Experiment 
number 
1 
2 
3 
4 
5 
1 
2 
3 
1 
2 
Cell trans-
formation 
2.3 
2.5 
5.5 
6.5 
5.5 
3.2 
3.5 
3.0 
3.0 
3.5 
TCIDso'ml) 
EBNA 
detection 
8.5 
8.5 
9.5 
9.5 
8.5 
4.5 
4.0 
5.5 
4.0 
5.0 
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lymphocytes than in lymphocytes from adult seronegative donors. 
2.4.3 Reproducibility 
The reproducibility of assays for detection of infectious EBV in lymphocytes from EBV-
seronegative donors was studied in samples obtained at bimonthly intervals. The 
reproducibility of EBNA detection was better than that for cell transformation in donor T, 
but was similar in donors J and E (table 2). 
2.4.4 DNA hybridization 
The detection level for EBV in the standard inoculum in dot-blot hybridization was 
determinded by testing two-fold dilutions in duplicate, and was found to be equivalent with 
2.5 4ogTCID5(j'ml in cell transformation, and therefore, far below that of the cell culture 
system. 
2.5 DISCUSSION 
Quantitation of EBV excretion requires a standardized cell culture system with a high 
sensitivity (12). When used for diagnostic purposes the incubation period should be as short 
as possible. Using cord blood lymphocytes, infectious EBV was detected 5 days earlier by 
EBNA detection than by cell transformation. The maximum EBV titer by EBNA detection 
was found between two and five weeks after inoculation (figure 1) and exceeded the titer by 
cell transformation by 1.0 to 4.0 4ogTCID5(y'ml. Thus, EBNA detection seems to have a 
higher sensitivity. 
The maximum EBV titer by EBNA detection was reached about 7 days earlier in cord blood 
lymphocytes than in lymphocytes from adult seronegative donors. Therefore, cord blood 
lymphocytes seem to be more susceptible to EBV infection than lymphocytes from adult 
seronegative donors. These differences may be due to variations in the T- and B-cell 
lymphocyte composition of the samples used. Spontaneous clumping of uninfected 
lymphocytes from a seronegative donor was observed once. The reason for this is unclear, but 
might be due to the addition of foetal calf serum in the culture medium (Pope, personal 
communication). 
We have shown that cord blood lymphocytes obtained from different donors exhibit a large 
variation in sensitivity to infection with EBV. At 3 weeks after inoculation virus titers 
ranged from 1.5 to 7.5 4ogTCID5(/ml as determined by cell transformation, and from 2.5 to 
9.5 4ogTCID5(/ml by EBNA detection. Similar results have been reported by other 
investigators (12). Corresponding variation was observed when lymphocytes from different 
adult EBV-seronegative donors were used. This might also be due to the variation in T/B-
cell ratio. The susceptibility of BJAB cells for EBV was less than that of cord blood 
lymphocytes or lymphocytes from adult EBV-seronegative donors since titers did not exceed 
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3.5 4ogTCID5(/ml. In addition, these cells have to be diluted weekly because of spontaneous 
outgrowth and they show a very low percentage of positive cells by EBNA detection. 
Therefore, BJAB cells are less useful for EBV infectivity assays. 
In contrast with the large variation in EBV susceptibility of lymphocytes from different 
seronegative donors, the results obtained in samples from the same donor at bimonthly 
intervals by EBNA detection were highly reproducible. The use of adult EBV-seronegative 
donor lymphocytes permits collection of a large amount of lymphocytes by either repeated 
donations or leuko-phoresis. This may improve standardization and is preferred to the use of 
cord blood lymphocytes which are limited by the available volume as well as variations 
between samples. 
The demonstration of EBV-specific DNA sequences by hybridization may in principle be 
used as an alternative to cell transformation and EBNA detection. This method has the 
advantage that cell culture facilities are not needed. However, in our hands, the sensitivity of 
dot-blot hybridization was quite low. The polymerase chain reaction technique (17,18) may 
increase sensitivity considerably and raise it to an acceptable level. 
Lymphocytes from adult EBV-seronegative donors are at least as suitable for quantitation of 
infectious EBV as cord blood lymphocytes. Moreover, they allow better standardization of 
the assay. However, in order to obtain maximum sensitivity donors have to be selected with 
lymphocytes that are highly sensitive for EBV infection. The virus must be detected by the 
EBNA technique or polymerase chaîne reaction. 
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CHAPTER 3 
DETECTION OF EPSTEIN-BARR VIRUS IN DONOR BONE MARROW AFTER 
IMMUNOREACTIVE LYMPHOCYTE DEPLETION BY COUNTERFLOW 
CENTRIFUGATION1 
3.1 SUMMARY 
Large myeloid element (stem cells) fractions obtained from donor bone marrow by 
counterflow centrifugation, were examined for the presence of Epstein-Barr virus (EBV). 
Peripheral lymphocytes and throat washings were also investigated for the presence of EBV. 
In addition sera were examined for antibodies to EBV. Of fifteen consecutive donors one had 
no EBV antibodies. EBV was detected in stem cells from eight of the fourteen EBV-
seropositive donors. Therefore, it is possible to transmit EBV in bone marrow transplant 
despite lymphocyte depletion by counterflow centrifugation. No relation was found between 
EBV-immune status, detection of EBV in throat washings or peripheral lymphocytes from 
the donor and the presence of EBV in the stem cell fraction. No significant differences were 
found in EBV-immune status or oropharyngeal EBV-excretion between patients receiving 
bone marrow with or without EBV. 
G. Weers-Pothoff, M.H.L.M. de Bruijn, T. de Witte, A.V.M.В. Schattenberg, 
A.M. van Loon. Presented at the International Conference Epstein-Barr 
Virus the first 25 years, Oxford, 1989. 
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3.2 INTRODUCnON 
Recipients of bone marrow transplants (BMT) experience profound immunosuppression in 
the first month after transplantation and are therefore highly susceptible to a variety of 
infections. Herpesvirus infections have been well documented in this group of patients mostly 
as a consequence of reactivation of herpes simplex virus (1), varicella-zoster virus (2) or 
cytomegalovirus (3). Primary infection with cytomegalovirus has also been described (3). Like 
other herpesviruses Epstein-Barr virus (EBV) persists after infection and can be recovered 
from peripheral lymphocytes and from oropharyngeal washings (4). The virus may be 
transmitted by bone marrow cells (5,6), or blood products (7,8). 
Separation of immunoreactive lymphocytes from human pluripotent stem cells by 
counterflow centrifugation (9,10) results in the presence of less than one percent of B-
lymphocytes, thus reducing the likelihood of EBV transfer. 
To examine whether EBV may be transmitted by bone marrow cells, we investigated the 
large myeloid element (stem cell) fraction of donor bone marrow obtained after counterflow 
centrifugation. Peripheral lymphocytes, and throat washings were also investigated for the 
presence of EBV in both donors and recipients. In addition, we examined their immune 
status with respect to EBV. 
3.3 PATIENTS AND METHODS 
3.3.1 Patients 
Fifteen consecutive patients (10 men, 5 women) receiving an allogeneic bone marrow 
transplant were studied. The mean age was 30.7 (range 13 to 42) years. 
3.3.1.1 Indications for transplantation 
The indications for transplantation were: acute myeloid leukemia in four patients of which 
three were in first complete remission (CRj), and one was in second complete remission 
(CR2); acute lymphoblastic leukemia in eight patients of which four were in CRi, two in 
CR2, one in third complete remission and one in partial remission; refractory anaemia with 
an excess of blasts in transformation in one patient in CRi, and lymphoblastic lymphoma in 
two patients of which one was in CRi, and one in fifth complete remission. 
3.3.1.2 Conditioning 
The conditioning regimen for fourteen patients consisted of cyclophosphamide, 
anthracyclines and fractionated total body irradiation as described previously (11). One 
patient was conditioned with cyclophosphamide and busulfan (12). 
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3.3.1.3 Immunoprophylaxis 
All patients received cyclosporin A for immunoprophylaxis as described previously (13). 
3.3.1.4 Blood products 
Six patients received two units of irradiated (20Gy) leukocyte-poor (<5xl0 /1) erythrocyte 
concentrates immediately prior to transplantation. All patients regularly received irradiated 
and leukocyte-poor erythrocyte and thrombocyte concentrates post-transplantation until no 
longer required. One to two units of fresh frozen plasma per day were given in the 
immediate post transplant period (day 0 to 14). 
3.3.1.5 Herpes prophylaxis 
All recipients received acyclovir as prophylaxis for herpes virus infection at an oral dose of 
4x400 mg/day or intravenously 3x500 mg/day from day minus 7 to plus 60 post 
transplantation. 
3.3.2 Materials and methods 
3.3.2.1 Bone marrow 
Bone marrow was obtained from the donors on the day of transplantation. After separating 
the cells by counterflow centrifugation (9,10), 2x10 stem cells were retained for 
examination. The cells were cultured at a concentration of 2x10 cells/ml in growth medium 
in 24 well plates (Costar 3424). Growth medium consisted of RPMI-1640 (Gibco) with 
addition of 10% fetal calf serum (Flow laboratories), 100 U/ml penicillin, 50 ug/ml 
gentamicin, 100 pg/ml vancomycin, 2.5 pg/ml amphotericin B, and 0.1 yg/ml cyclosporin 
A. One part of the cells was examined by microscopy for spontaneous EBV-induced 
transformation (immortalization) weekly. The other half was inoculated with the supernatant 
of B95-8 cells, that resulted from three times freezing and thawing. Subsequently they were 
examined for transformation weekly. In both assays 30% of the growth medium was replaced 
once weekly. After 8 weeks the cells were examined for Epstein-Barr nuclear antigen 
(EBNA) as described by Reedman and Klein (14). 
3.3.2.2 Peripheral lymphocytes 
Peripheral lymphocytes were isolated from 10 ml venous blood by use of Ficoll-Paque 
(Pharmacia). They were diluted to 2x10 cells/ml in growth medium and seeded in 96 well 
microtitration plates (Costar 3595). During leukopenia (i.e. leukocytes <0.1xl0 cells/I) less 
cells were obtained what resulted in unreliable results. Examination for transformation of 
cells and for EBNA was performed as described for bone marrow cells. 
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3.3.2.3 Throat washings 
Throat washings were obtained from donors by gargling with 10 ml of RPMI-1640 one day 
before transplantation, and from recipients, 8 days before transplantation and on days 8, 12, 
19, 26, 33 thereafter. Further specimens were obtained 3, 6, 9 and 12 months after 
transplantation. After centrifuging the sample at 2000xg, the supernatant was passed through 
a 45 μ filter and 15% of foetal calf serum was added to the filtrate. The filtrate was stored at 
-70oC until use. 
To examine these samples for EBV they were quickly thawed and centrifuged at 100,000xg at 
40C for 2 hours. Serial tenfold dilutions (10 to 10~5) were made from the pellet in growth 
medium without cyclosporin A, and 150 μΐ of each dilution was added to wells containing 
100 μΐ of 2x10 lymphocytes/ml obtained from an EBV-seronegative donor. Cultures were 
examined for "spontaneous transformation". Thereafter, 30% of the growth medium was 
replaced once weekly. EBNA detection was performed after three weeks. 
3.3.2.4 Serum samples 
Venous blood samples were obtained from donors and recipients at the same time as were 
throat washings. IgG-, IgM-, and IgA- antibodies against the viral capsid antigen (VCA) and 
anti-early-antigen antibodies (anti-EA) were detected by an immunofluorescence assay (15) 
using induced НН514-СІ6 cells (kindly provided by J. Middeldorp, originating from G. 
Miller) as a substrate (16,17). Anti-EBNA was detected on Raji cells by an anticomplement 
immunofluorescence technique as described by Reedman and Klein (14) and modified by 
Henle et al (18). Control assays for non-specific reactions of all sera were carried out on 
BJAB cells (19). 
3.4 RESULTS 
Four BMT recipients died on days 19, 33, 44, and 62 after transplantation of causes unrelated 
to EBV infection. All other recipients were followed during a period of 6 to 14 months. One 
donor-recipient pair did not have serological evidence of previous EBV infection, while all 
other pairs (n = 14) had detectable antibodies to EBV. 
3.4.1 Donors 
"Spontaneous transformation" was detected in the stem cell fractions of eight of the fourteen 
seropositive donors (table 1). EBV-susceptible cells were present in samples from all 14 
donors. 
Peripheral lymphocytes were available from six of the eight donors with "spontaneous 
transformation" of the stem cell fraction. In five of these samples "spontaneous 
transformation" of the peripheral lymphocytes was observed (table 1). Throat washings were 
48 
Table 1. Number of donors with "spontaneous transformation" of stem cells, of peripheral 
lymphocytes and with excretion of EBV in the throat. 
recipient 
number 
С 
E 
F 
L 
О 
S 
W 
X 
A 
В 
H 
К 
N 
Y 
donor stem 
cells 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
_ 
-
-
-
-
-
spontaneous transformation of 
peripheral 
lymphocytes 
NA 
+ 
NA 
+ 
+ 
+ 
-
+ 
+ 
-
NA 
+ 
-
-
throat 
washing 
NA 
NA 
NA 
NA 
+ 
+ 
-
+ 
NA 
NA 
NA 
NA 
NA 
+ 
NA 
EBV not detectable 
EBV dectectable 
no sample available 
available from only three of these five. In all these three, EBV was present as indicated by 
their capability to transform EBV-negative lymphocytes. No transforming activity was found 
in the throat washing from the donor whose peripheral lymphocytes showed no "spontaneous 
transformation". 
Of the six donors without "spontaneous transformation" of stem cells, peripheral lymphocytes 
were available from five. In two of these samples "spontaneous transformation" of 
lymphocytes was observed (table 1). No throat washings were obtained from these two 
donors. A throat washing was obtained from one donor without "spontaneous transformation" 
of peripheral lymphocytes and was found positive for infectious EBV. No difference in EBV 
antibody levels was detected between the two donor groups with and without EBV in their 
stem cell fraction (table 2). 
3.4.2 Recipients 
"Spontaneous transformation" of peripheral lymphocytes was detected in three of fourteen 
recipients in the pre-transplantation period. Assays conducted during leukopenia were 
unreliable since there were insufficient cells in the 10 ml of peripheral blood. 
Virus was detectable in the throat washings from four of twelve recipients before 
transplantation (table 3). In eleven of twelve recipients it was found in at least one sample 
during leukopenia (table 3) and in ten of thirteen samples obtained after leukocyte recovery 
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Table 2. EBV antibody levels of donors. 
donor 
number 
С 
E 
F 
L 
О 
S 
W 
X 
A 
В 
H 
К 
N 
Y 
"sponstaneous 
transformation" 
of stem cells 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
_ 
-
-
-
-
-
IgG 
VGA 
64 
512 
256 
128 
512 
128 
32 
128 
128 
64 
32 
128 
512 
256 
EBV antibody 
IgA 
VGA 
<8 
<8 
32 
16 
<8 
<8 
<8 
32 
<8 
<8 
<8 
8 
8 
<8 
titers* 
anti-
EA 
<8 
8 
<8 
<8 
<8 
<8 
<8 
8 
<8 
<8 
16 
<8 
16 
<8 
anti-
EBNA 
32 
64 
16 
64 
128 
64 
256 
256 
32 
32 
64 
64 
512 
128 
IgM antibody to EBV-VCA was lacking in all donors; titers are given as the 
reciproke of the highest dilution in which antibodies were detected 
positive 
negative 
(table 3). Levels of IgG-VCA and anti-EBNA varied in all BMT recipients. During 
leukopenia and marrow recovery no specific antibody patterns could be detected. Most levels 
fluctuated within one or two dilutions of their original level. No patient became seronegative 
for either antibody. Anti-EA was detectable in two of fourteen recipients before 
transplantation. No specific patterns of anti-EA response could be found in recipients of 
stem cells with or without "spontaneous transforming" cells. 
The EBV-seronegative recipient obtained stem cells from an EBV-seronegative donor and 
cultures from both showed no evidence of the virus. However, this recipient did acquire 
transient IgG-VCA and anti-EBNA, from 8 to 90 days post-transplantation. Anti-EA was 
only detected in the sample of day 8. 
3.5 DISCUSSION 
"Spontaneous transformation" was detected in the stem cell fraction obtained after 
counterflow centrifugation in eight of fourteen EBV-seropositive donors. Therefore, EBV 
may be transmitted by these cells. These results are in accordance with data from Ragona et 
al (6), but not with those from Baranski et al (20). An explanation for this discrepancy might 
50 
Table 3. Detection of EBV in throat washings of BMT recipients 
icvipicii i 
number 
С 
E 
F 
L 
О 
S 
w X 
A 
В 
H 
К 
N 
Y 
_ 
+ 
NA 
spontaneous 
transplantation" 
of donor stem 
cells 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
_ 
-
-
-
-
-
EBV not detectable 
EBV detectable 
sample not available 
pre­
plan tation 
_ 
-
-
-
+ 
+ 
NA 
-
+ 
-
-
NA 
+ 
-
post-transplantation 
leukopenia 
+ 
+ 
+ 
+ 
NA 
+ 
NA 
+ 
+ 
-
+ 
+ 
+ 
+ 
post-
leukopenia 
-
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
NA 
+ 
+ 
+ 
-
be the absence of cyclosporin A in their culture medium. In addition, the stem cell fraction 
from all donors contained EBV-susceptible cells. This does not prove that stem cells were 
infected, since the stem cell fraction contains also B-lymphocytes, albeit in very low 
numbers, that can be infected with EBV. Further investigations are required to determine the 
exact nature of the EBV-infected or -susceptible cells in the stem cell fraction. 
"Spontaneous transformation" of peripheral lymphocytes and excretion of EBV in the throat 
was observed in samples from donors irrespective of the presence of EBV in the stem cell 
fraction. Few data were available and comparison of antibody levels in both groups did not 
reveal differences. Therefore, these assays do not appear to be predictive for the presence of 
EBV in the stem cell fraction. 
"Spontaneous transformation" of peripheral lymphocytes from recipients occurred 
infrequently in the pre-transplant period. Oropharyngeal excretion of EBV did not differ 
between patients receiving stem cells with or without "spontaneous transformation". Acyclovir 
did have no inhibiting effect on EBV-excretion in the throat. The serological data failed to 
reveal significant changes in antibody levels for IgG-, IgM-, IgA-VCA, and anti-EBNA in 
BMT patients. Neither was there a large increase in IgG-VCA nor a decrease in anti-EBNA 
titers as observed by Lange et al (21) and Morinet et al (22). The difference in the course of 
antibody titers may be explained by using counterflow centrifugation resulting in a low 
amount of transplanted B- and T-lymphocytes. One EBV-seronegative recipient whose donor 
was also seronegative acquired transient IgG-VCA, anti-EA, and anti-EBNA antibodies 
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which had disappeared after three months. Passive transfer of EBV antibodies by transfused 
blood products or fresh frozen plasma may explain this observation. Therefore, evaluation of 
antibody levels within three months of transplantation, or soon after a transfusion, does not 
seem to be useful. 
Our results show that it is possible to transmit EBV by the stem cell fraction of bone marrow 
despite lymphocyte depletion by counterflow centrifugation. The demonstration of 
transfonning peripheral lymphocytes and of EBV in throat washings did not appear to 
correspond with the EBV-status of the stem cell fraction. Further studies should be carried 
out to determine the exact nature of the EBV-infected or -susceptible cells in the stem cell 
fraction. 
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CHAPTER 4 
SEROLOGICAL AND VIROLOGICAL FOLLOW-UP OF PATIENTS WITH INFECTIOUS 
MONONUCLEOSIS1 
4.1 SUMMARY 
The oropharyngeal excretion of Epstein-Barr virus (EBV) and the EBV-specific antibody 
response was studied in a group of 45 patients with infectious mononucleosis (IM, group 1) 
for a period of 18 months after onset of symptoms. A further group of 11 patients with signs 
and symptoms suggestive of IM but without serologic confirmation of a recent primary EBV 
infection (group 2) was also studied longitudinally. In addition samples from 20 healthy 
laboratory workers (group 3) were investigated. IgM antibody to the viral capsid antigen 
(VCA) was present in the first serum sample of all patients with IM and in none of the sera 
from the other groups. IgM-VCA persisted between 0.5 and 9 months. An IgA-VCA 
response was found in 35 (78%) patients in group 1 and persisted at 18 months in 2 of the 17 
(12%) individuals whose follow-up was complete. The prevalence of IgA-VCA in group 2 
was between 20% and 50% and in the third group 20%. IgG-VCA was detected in all sera 
from all groups. Antibody to the EBV-early antigen (anti-EA) was detected in 43 (96%) 
patients in group 1 and persisted at the end of the study in 11 (65%) of 17 patients. The 
prevalence of anti-EA in group 2 was between 20% and 57% and in the third group 50%. 
Antibody to the EBV nuclear antigen (anti-EBNA) was present in 7 of 20 (35%) patients of 
group 1 within 2 weeks after start of symptoms and in 43 (96%) patients six months after 
onset. Anti-EBNA was detectable in all sera of both groups 2 and 3. Heterophile antibodies 
were detected in 41 (91%) of the first samples of group 1 patients and in none of the 
individuals of groups 2 and 3. A significant difference in titers for IgA-VCA and anti-EA 
between groups 1 and 3 was detected in the first available sample obtained within 1 month 
after onset of illness. 
All patients with IM excreted EBV from their throat as did 90% iind 75% of groups 2 and 3, 
respectively. Differences in viral titers between groups 1 and 3 were not significant. 
The presence of IgM-VCA or a seroconversion for anti-EBNA still appear to be the best 
markers of a primary EBV infection. On the other hand quantitation of EBV excretion in 
throat washings, detection of IgA-VCA and anti-EA seems to be of little diagnostic value. 
G. Weers-Pothoff, M.H.L.M. de Bruijn, A.J.A. van Griethuysen, M.F. Peeters, A.M. 
van Loon. Presented at the First National Organon Symposium: New Developments in 
Virology, Oss, 1989. 
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4.2 INTRODUCTION 
Over the last few years attention has been focused on the chronic fatigue syndrome (CFS) 
and the aetiological role of Epstein-Barr virus (EBV) (1-6), and enteroviruses (7). Several 
studies of the EBV-specific antibody response in patients with CFS showed elevated titers of 
IgG antibody to the viral capsid antigen (VCA) (1,2,8-10), of IgM-VCA (1-3,10), and of 
antibody to the EBV-early antigen (anti-EA) (1,2,8-10) and low titers of antibody to 
Epstein-Barr virus nuclear antigen (anti-EBNA) (1,2,9,10). The differences were significant 
for the group of CFS patients as a whole. Conclusions for individual patients could not be 
drawn because the range of titers between the patient and control groups overlapped 
(1,4,8,9). 
Some investigators have suggested that quantitation of EBV excretion in the throat might be 
more valuable for diagnosing active infection (4,11). However, results from virus excretion 
studies in patients suspected of recurrent or chronic EBV infection should be compared with 
those obtained in healthy persons with prior EBV infection and persons with a recent EBV 
infection. 
To assess the significance of EBV serological markers and quantitation of EBV excretion in 
throat washings we studied consecutive samples from patients with a recent EBV infection 
(group 1), a group with similar symptoms but without serological indications of recent or 
active EBV infection (group 2) and single samples from a group of healthy laboratory 
employees (group 3). The presence of IgG-, IgM-, IgA-VCA, anti-EA, anti-EBNA and 
heterophile antibodies in serum, and the excretion of EBV in throat washings were 
determined. In addition we studied the relationship between EBV serology, virus excretion 
and clinical symptoms. 
4.3 PATIENTS AND MCTHODS 
4.3.1 Patients 
Seventy-three consecutive patients from several general practioners in the region of the city 
of Tilburg and from several general practitioners in the region of the city of Nijmegen who 
fulfilled a number of the signs (fever, lymphadenopathy, splenomegaly, hepatomegaly, peri-
orbital swelling, exanthema) and the symptoms (fatigue, headache, sore throat, cough, 
anorexia, myalgia, sweats, abdominal discomfort) suggestive of infectious mononucleosis (IM) 
were asked to enter the study. Forty-one patients had a positive heterophile antibody test. 
Fourteen patients refused, three had no EBV antibodies at all and eleven patients had 
serological markers consistent with past infection. Of the forty-five remaining patients 
(group 1) there were 19 men [mean age 21.9; range 10 to 39], and 26 women [mean age 17.5 
range; 11 to 27]. The clinical diagnosis of IM was confirmed by EBV-specific serology at 
first presentation or by the EBV-antibody course. Patients were considered to have a recent 
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primary EBV infection on the basis of one or more of the following criteria: the presence and 
subsequent decline of IgM antibody to VCA in their serum, a transient anti-EA response, or 
a sero-conversion of antibody to EBNA in the presence of IgG antibody to VCA. A further 
group of 11 patients with cervical lymphadenopathy and/or fever, symptoms suggestive of a 
primary EBV infection and IgG-VCA detectable in their serum but without serological 
markers consistent with recent infection was recruited (group 2). This group consisted of 3 
men [mean age 21.3; range 20 to 22], and 8 women [mean age 19.5; range 15 to 27]. A third 
group comprised 20 healthy laboratory workers (group 3) consisting of 5 men [mean age 36.6; 
range 30 to 44] and 15 women [mean age 32.2; range 25 to 41] from whom a single serum 
sample and throat washing was obtained. Sera from patients were obtained at their first visit 
and 2, 4, 6, 9, 12, and 15 or 18 months after the onset of symptoms. The sera were stored 
at -20oC. 
Samples for virus isolation were obtained from all individuals by gargling with 10 ml of 
tissue culture medium (RPMI-1640, Gibco). A full history was taken with special attention 
given to the occurrence of the symptoms fatigue, headache, sore throat, cough, anorexia, 
myalgia, sweats and abdominal discomfort. Additionally, all subjects were given a physical 
examination with special attention to the signs fever, lymphadenopathy, splenomegaly, 
hepatomegaly, peri-orbital swelling and exanthema. 
4.3.2 Laboratory methods 
4.3.2.1 Serology 
Heterophile antibodies were determined as described by Paul and Bunnell (12) and Davidsohn 
(13) using sheep red blood cells. A titer of >1:40 was considered positive. IgG-, IgM-, IgA-
VCA and anti-EA were detected by an indirect immunofluorescence assay (14) using induced 
НН514-СІ6 cells (kindly provided by Dr J. Middeldorp, originating from Dr G. Miller) a s a 
substrate (15,16). Anti-EBNA was determined on Raji cells by the anticomplement-
immunofluorescence assay as described by Reedman and Klein (17) and modified by Henle 
et al (18). The reaction was read independently by two experienced persons. The lowest titer 
was accepted if there was a discrepancy of one dilution whereas the assay was repeated if a 
larger discrepancy occurred. 
4.3.2.2 Virus isolation 
Throat washings were centrifugated at 2,000xg for 10 min after which the supernatant was 
passed through a 0.45 y filter, and stored at -70oC in 15% foetal calf serum (19). When 
required for virus isolation, samples were quickly thawed and centrifuged at lOO.OOOxg at 
40C for 2 hours (19). After re-suspension of the pellet, serial 10-fold dilutions (10"1 to 10"5) 
were made and aliquots of 150 μΐ were added to wells containing 2x105 lymphocytes from an 
EBV-seronegative donor. Thirty percent of the growth medium was replaced weekly and the 
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Table 1. Presence of serological markers of EBV infection in samples from patients with IM 
(group 1) from whom sera were collected within 1 month after onset of symptoms (n=33) and 
from healthy laboratory workers (group 3) (n=20). From group 2 too few samples were 
available. 
IgM-VCA 
IgA-VCA 
IgG-VCA 
anti-EA 
anti-EBNA 
heterophile 
antibodies 
group 1 
11 J J 
positive 
η 
33 
26 
33 
27 
14 
30 
% 
(100) 
(79) 
(100) 
(82) 
(42) 
(91) 
group 3 
11-¿U 
positive 
η 
0 
4 
20 
10 
20 
0 
% 
( 0) 
(20) 
(100) 
(50) 
(100) 
( 0) 
for titer 
level 
< 0.01 
<0.01 
<0.01 
< 0.05 
<0.01 
<0.01 
ρ value 
for positive/ 
negative 
< 0.01 
< 0.01 
n.s. 
<0.05 
< 0.01 
< 0.01 
cells were examined for signs of virus-induced transformation. Three weeks after inoculation 
the cells were fixed in order to detect EBNA as described by Reedman and Klein (17). The 
amount of virus in throat washings was given as the last dilution in which EBV was 
detectable. 
4.3.3 Statistical analysis 
For statistical analysis the test of Gehan (20) and the Chi-square test were used. 
4.4 RESULTS 
4.4.1 Serology 
Because it was not possible to sample sera and throat washings at the selected time for all 45 
patients the number of tested samples varies. 
IgM-VCA was detected in all sera collected from patients with IM sampled within one month 
after onset of symptoms (table 1). Thereafter the prevalence of IgM-VCA started to decline 
(figure 1). The shortest duration of IgM-VCA detection was 2 weeks, the longest 9 months 
after onset of symptoms. In groups 2 and 3 IgM-VCA was not detected in any serum sample 
(figure 2). IgA-VCA was not detected in eight (18%) of the 45 patients of group 1. In one 
patient it was detected only 14 days after onset of symptoms. The decrease of IgA-VCA was 
similar to that of IgM-VCA for the first б months (figure 1). However, in 2 of 17 (12%) 
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Figure 1. Follow-up of the prevalence of EBV-speciflc- and heterophile antibodies in sera of 
patients with IM (group I). N - number of tested samples. 
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Figure 2. Follow-up of EBV-speciflc- and heterophile antibodies in sera of patients with 
complaints suggestive of IM without serologic markers of a recent EBV infection (group 2). N 
= number of tested samples. 
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Table 2. Titers of IgA-VCA and anti-EA in samples obtained from patients with IM (group 1) 
within one month after onset of illness and from healthy laboratory workers (group 3). 
IgA-VCA anti-EA 
titer group 1 group 3 group 1 group 3 
n=33 n=20 n=33 n=20 
256 
128 *** *** 
64 «.***** * ****' 
32 ****** * *** 
**** 
16 *** ****' 
8 * * ** 
**** 
* ****** 
<8 ****** ****** ****' 
ρ value <0.01 <0.05 
patients with complete follow-up IgA-VCA persisted till the end of the study. In sera from 
group 2 the presence of IgA-VCA varied between 20% and 50% (figure 2), while in group 3 
it was 20%. The titers of IgA-VCA of the first samples from patients in group 1 ranged from 
<1:8 to 1:256 and for the single samples from the persons of group 3 from < 1:8 to 1:128 (table 
2). The geometrical mean titers showed a significant difference (p<0.05). In group 2 to few 
samples were available for statistical analysis. 
IgG-VCA was present in all samples of all groups. An increase and subsequent decrease of 
IgG-VCA in group 1 was detected in 20 (44%) patients, a stable level in 16 (36%) and a high 
level of antibody at onset of symptoms followed by a decrease in 9 (20%). The titers ranged 
from 1:8 to 1:2048 in all groups. However, there was a significant difference (p<0.01) in the 
mean titers of samples obtained in the first month after onset of symptoms of group 1 and 
those of group 3 (table 1). Anti-EA could not be detected in sera of two patients in group 1. 
In three it was found for the first time at 0.5, 1.5, and 3 months after onset of symptoms, 
respectively. At the end of the follow-up period 11 of 17 (65%) patients still had detectable 
anti-EA levels (figure 1). In the follow-up sera from group 2 the prevalence varied between 
20% and 57% (figure 2), and was 50% in the samples of group 3. The titers of the first 
positive samples of group 1 and the single samples of group 3 were between <1:8 and 1:256 
*** 
** 
** 
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Figure 3. Follow-up of virus excretion in patients of groups 1 and 2 and single detection in 
persons of group 3. On top of bars total of samples tested. 
(table 2). The geometrical mean titers between these two groups differed significantly 
(p<0.05). In group 2 not enough samples were available for statistical analysis. 
Two weeks after the onset of illness, anti-EBNA was present in 7 of 20 (35%) patients 
(figure 1) while 43 of 45 (91%) patients had detectable anti-EBNA in their serum within 6 
months. Seroconversion was observed after 10 months in the sera of the two remaining 
patients. The antibody titer generally rose during the first 4 months and stabilized at a mean 
titer of 1:64 (range 1:2 to 1:512). The geometrical mean titer of group 3 was 1:73 and the titer 
varied from 1:4 to 1:1024. 
Heterophile antibodies were detected in the first serum samples of 41 (91%) patients of group 
1 (figure 1). In one patient these antibodies were not detected at all. Four months after onset 
of symptoms heterophile antibodies were detected in 15% of these patients. None were 
detected in any sample of groups 2 and 3. 
4.4.2 Oropharyngeal shedding of EBV 
EBV was detected in 67% of the samples from patients of group 1 obtained within 1 month 
after onset of illness. Oropharyngeal shedding increased to 91% after 3 months (figure 3) and 
varied between 91% and 95% during follow-up from 3 to 18 months. Twenty-two (49%) 
patients of group 1 excreted virus in all tested samples. In group 2 EBV excretion was found 
in 10 of 11 patients. In 3 (30%) it was detected consistently in all samples. In group 3, fifteen 
(75%) out of 20 subjects excreted EBV. During follow-up of groups 1 and 2 the titers ranged 
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Table 3. Prevalence of signs and symptoms (%) in patients of groups 1 and 2 in relation to 
onset of disease (0) and after three (3) and five (5) months. 
months after onset of symptoms 
signs 
fatigue 
sweats 
sore throat 
headache 
anorexia 
myalgia 
abdominal discomfort 
cough 
symptoms 
lymphadenopathy cervical 
fever 
lymphadenopathy gegeneralized 
hepatomegaly 
splenomegaly 
peri-orbital swelling 
exanthema 
0 
100 
74 
71 
61 
58 
52 
45 
36 
87 
71 
21 
46 
37 
10 
0 
group 
3 
64 
17 
5 
14 
14 
12 
29 
10 
41 
5 
17 
30 
22 
2 
0 
1 
5 
41 
5 
8 
5 
3 
3 
5 
0 
15 
0 
3 
0 
0 
0 
0 
0 
100 
100 
100 
33 
33 
33 
33 
33 
60 
67 
0 
0 
0 
0 
0 
group 2 
3 
67 
11 
22 
11 
11 
0 
11 
11 
22 
0 
0 
0 
0 
0 
0 
5 
38 
25 
0 
0 
25 
13 
0 
13 
13 
0 
0 
0 
0 
0 
0 
from 10"1 to £10'5. In group 3 they varied from 10"1 to IO"4. There was no correlation 
between the excretion of EBV and any of the EBV specific serological markers. 
4.4.3 Clinical symptoms, signs and physical examination 
The clinical signs and symptoms at onset of disease and at 3 and 5 months thereafter are 
given in table 3. Peri-orbital swelling was observed in 10% in patients of group 1, abdominal 
discomfort, cough, generalized lymphadenopathy, hepatomegaly, and splenomegaly between 
20% and 50% and all other signs and symptoms between 50% and 100%. Three months after 
onset of illness, fatigue and cervical lymphadenopathy were still present in more than 40% of 
cases while fever, peri-orbital swelling, cough, hepato- and splenomegaly were no longer 
detectable after four months. Headache, sore throat, myalgia, sweats, abdominal discomfort, 
and generalized lymphadenopathy had disappeared after eight months, and fatigue and 
cervical lymphadenopathy after nine months. In group 2 the prevalence of signs at onset did 
not differ markedly from those of group 1. Cervical lymphadenopathy and fever were the 
only symptoms detected in group 2. In this group, 3 months after onset of illness fever was 
not longer detectable while after 5 months 13% of patients still had cervical 
lymphadenopathy. 
No correlation was found between clinical signs and symptoms and virus excretion in the 
throat. 
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4.5 DISCUSSION 
The clinical signs in our group of 45 patients with IM are in accordance with data from other 
investigators (21). However, they are not very specific for a primary EBV infection since a 
similar pattern of signs was found in patients in whom primary EBV infection was excluded 
by serology. Peri-orbital swelling was a symptom only detected in IM patients. Cervical 
lymphadenopathy and fever were the only symptoms occurring in group 2. The percentage of 
clinical signs decreased at a similar rate in groups 1 and 2. After 5 months nearly all patients 
were free of complaints. These data indicate by definition that patients of group 2 did not 
suffer from CFS (22). 
IgM-VCA was detected in group 1 in all samples obtained within 1 month after onset of 
illness and appeared to be the best marker of primary infection. Heterophile antibodies were 
detected in 91% of patients with IM thus limiting the usefulness of this test. The decline of 
both markers was similar and they were rarely detected more than 6 months after onset of 
illness. 
A prevalence of 79% for IgA-VCA in patients with IM which declined sharply during four 
months settling to 12% is in accordance with earlier observations (23,24). IgA-VCA was 
found in 20% to 50% of sera from patients in group 2 and in 20% in subjects of group 3. The 
prevalence and mean titers of IgA-VCA in IM patients and group 3 differed significantly 
(p<0.01). However, the range was equal in both groups thus limiting the diagnostic value for 
active disease in individuals. 
Our data for IgG-VCA showed an increase followed by a subsequent decrease, a decrease or 
a stable titer during the follow-up period for individual patients of group 1. However, all 
titers remained positive. Other investigators (25) found that levels of IgG-VCA started to 
decline 14 months after onset of symptoms, thus our follow-up may not have been long 
enough. Although there was a significant difference in geometrical mean titers between 
samples from IM patients and those from group 3 the range was equal for both groups. 
Therefore IgG-VCA does not appear to be a suitable marker for detection of a recent EBV 
infection. 
The prevalence of anti-EA in 82% of 33 patients with IM in samples obtained within one 
month after onset of illness was equal to that found by others (26) and the persistence rate of 
65% at the end of the follow-up period showed agreement also (25). Anti-EA was detected 
between 20% and 57% in group 2 and in 50% in group 3. While mean titers were significantly 
different (p<0.05) the range was identical between patients with IM and group 3. Therefore 
single determinations for anti-EA do not appear to be specific for recent EBV infection in 
individual patients. However, high titers both for IgA-VCA and/or anti-EA can be of value 
especially in early diagnosis of nasopharynx carcinoma (28,29). 
The presence of anti-EBNA in over 35% of 33 patients at onset was also reported by Sumaya 
(27). All patients with IM developed anti-EBNA during follow-up, albeit occasionally at very 
low titers or more than 10 months after onset of disease. Therefore a seroconversion indicates 
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a recent EBV infection. 
No difference in oropharyngeal EBV excretion was found between the group of patients with 
IM and the other groups, nor was there any correlation with serological parameters or clinical 
symptoms. The range of EBV titers weis similar for all three groups indicating that detection 
or quantitation of EBV excretion in throat washings is of little value in diagnosis. 
In our study the presence of IgM-VCA, heterophile antibodies or a seroconversion for anti-
EBNA appeared to be the best markers of a primary EBV infection. In view of the 
overlapping range of titers of IgG-VCA, IgA-VCA and anti-EA in IM patients and healthy 
individuals, application of these parameters for diagnosis of CFS seems of limited value. 
However, further studies in CFS patients should be carried out to corroborate this suggestion. 
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CHAPTER 5 
EVALUATION OF LABORATORY TESTS FOR DIAGNOSIS OF A PRIMARY EPSTEIN-
BARR VIRUS INFECTION IN A GENERAL PRACTICE ' 
5.1 SUMMARY 
Specific antibodies to EBV, -cytomegalovirus, -Toxoplasma gondii, heterophile antibodies, 
hematologic parameters and alanine transaminase (ALAT) activity were determined in sera 
obtained from 3 groups of patients. Group 1 consisted of patients with complaints suggestive 
of infectious mononucleosis (IM) (n=207), group 2 of those who had had contact with a 
patient with IM (n=9), and group 3 of those in whom IM had to be excluded (n=5). Twenty-
seven patients were considered to have a recent primary EBV infection. In 26 (11.8%) cases 
IgM antibody against the EBV capsid antigen (VGA) was detected and one (0.5%) case was 
positive for IgG-VCA in the absence of antibody against Epstein-Barr nuclear antigen. 
Determination of heterophile antibodies by the Paul-Bunnell-Davidsohn (PBD) test gave a 
sensitivity and specificity of 96% and 98%, by the beef hemolysin test of 93% and 98%, and 
by the Monosticon Dri-dot test of 85% and 98%, respectively, in relation to specific EBV 
antibodies. Using stepwise logistic regression analysis only a reduced proportion of 
granulocytes and an increase in ALAT were significantly correlated (p<0.05) with a primary 
EBV infection showing together a sensitivity of 75% and a specificity of 100%. 
Sore throat and peri-orbital swelling were selected having the best predictive value for signs 
and symptoms together having a sensitivity of 15%. None of the patients without complaints 
had serologic evidence of a primary EBV infection. The detection of heterophile antibodies is 
the first test to perform in patients presenting to their general practitioner with signs and 
symptoms indicative of IM. However, if clinical symptoms and the PBD test do not agree 
further investigation is necessary to diagnose the disease. 
1
 G. Weers-Pothoff, P.O. Dingjan, H.L.J. Nieste, Th.M. de Boo, A.M. van Loon. 
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5.2 INTRODUCTION 
The Epstein-Barr virus (EBV) is well documented as the causative agent of infectious 
mononucleosis (IM). It is an acute illness characterized by fatigue, sore throat, fever and 
lymphadenopathy, and by the development of specific antibodies to EBV, a transient 
appearance of heterophile antibodies, and by a mononuclear leukocytosis that consists, in 
part, of atypical lymphocytes (1). However, an individual case may not present with these 
symptoms and may present a quite different syndrome, which may result in the wrong 
diagnosis and/or necessitate extensive examination (2,3). A number of other diseases, some of 
infectious origin (e.a. cytomegalovirus infection, toxoplasmosis, rubella, hepatitis) may mimic 
the symptoms of primary EBV infection. The IM patient whose heterophile-antibody test is 
negative is frequently infected with cytomegalovirus (CMV) or Toxoplasma gondii (4). False-
positive reactions for heterophile antibodies have been detected in patients with hepatitis (5), 
rubella (6), malaria (7), rickettsial disease (8) and HIV (9) infection. Therefore, there is a 
need for sensitive and specific diagnostic laboratory tests. Laboratory assays used to confirm 
the clinical diagnosis need careful interpretation and must take into account the type of test 
used, symptoms, age of the patient and other laboratory parameters (2,3,10-14). 
The non-specific nature of the symptoms and the frequent requests for extensive laboratory 
examinations by general practitioners led us to investigate the value of different diagnostic 
assays for both EBV-specific and non-specific antibodies, and hematological- and 
biochemical parameters. We also examined sera for the presence of IgM antibody to CMV 
and Toxoplasma gondii. 
5.3 MATERIALS AND METHODS 
5.3.1 Patients 
The study included 221 patients from 20 general practitioners in the region of the city of 
Wageningen with a mean age of 20.9 years (range 1 to 61) and an interquartile range of 25 
years (figure 1). Patients were at first seen by their general practitioner. A standardized 
history was obtained and a physical examination was performed by the general practitioner 
(table 1). The ratio of male:female was 2:3. Criteria for entering the study were: (i) symptoms 
suggestive of IM (n=207, table 1), (ii) contact with a patient suffering of IM (n=9, of which 1 
had symptoms), (iii) exclusion of IM (n=5). 
5.3.2 Laboratory methods 
IgG-, IgM-, and IgA-antibody against the virus capsid antigen (VCA) and antibody against 
the EBV-early antigen (anti-EA) were detected using indirect immunofluorescence assays 
(15). Antibody against Epstein-Ban nuclear antigen (anti-EBNA) was detected with an anti-
complement immunofluorescence assay (16). A recent EBV infection was defined by the 
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6G 
50 
40 
30 
number 
^Ш suspected IM 
Е2/3 confirmed IM 
35 85 135 18 5 235 285 335 385 135 485 5Э5 5В5 635 
years 
Figure I. Age distribution of patients suspected and confirmed of having a primary EBV 
infection 
presence of IgM-VCA in a dilution of >1:8 and/or the presence of IgG-VCA in a dilution of 
£1:8 in the absence of anti-EBNA in a dilution of 1:2 (17). 
Heterophile antibodies were detected by the Paul-Bunnell-Davidsohn (PBD) test (18) using 
sheep erythrocyte, the hemolysin (BHL) test (19) using beef erythrocytes and the Monosticon 
Dri-dot (MDD) test (Organon Teknika) following the manufacturers' instructions. The PBD 
test and BHL test were defined to be positive by a titer of > 1:32 and > 1:120, respectively. 
A total and differential count of leukocytes (three part differentiation Cell-Dyn-1600, 
Sequoia-Tumer Corporation), atypical lymphocytes (manual differentiation), hemoglobin 
level (Hb), mean cell volume (MCV), number of thrombocytes and the alanine transaminase 
(ALAT) concentration were also determined. 
Antibody to CMV and Toxoplasma gondii were detected by an ELISA technique (20,21) and 
positive results were confirmed using immunofluorescence or immunoblotting tests. 
5.3.3 Statistical analysis 
Statistical analysis was performed with a chi-square test for the 2 χ к table using stepwise 
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Table 1. Symptoms and signs in patients with and without a proven infectious mononucleosis 
Symptoms 
fatigue 
cervical lymphadenopathy 
sore throat 
headache 
fever 
anorexia 
generalized lymphadenopathy 
myalgia 
peri-orbital swelling 
abdominal discomfort 
splenomegaly 
hepatomegaly 
exanthem 
anaemia 
sweats 
icterus 
*: significant difference (p < 0.05) 
logistic regression analysis. 
5.4 RESULTS 
Single samples of blood were obtained between 1 day and 170 days after onset of symptoms 
(interquartile ranges of 9 and 37 days). 
A recent primary EBV infection was diagnosed in 27 (12.3%) patients aged 8 to 26 years 
(figure 1). Twenty-six patients were diagnosed by a positive IgM-VCA and one by a 
combination of a positive IgG-VCA and a negative anti-EBNA test. In the samples of 22 
(81.5 %) and 23 (85.2 %) of these 27 patients, IgA-VCA and anti-EA were detectable, 
respectively. 
Statistical analysis showed there to be a significant difference (p<0.05) between patients with 
and without recent EBV infection for cervical lymphadenopathy, sore throat, headache, 
fever, anorexia, generalized lymphadenopathy, myalgia, peri-orbital swelling and 
splenomegaly (table 1). 
Stepwise logistic regression analysis resulted in sore throat and peri-orbital swelling having 
the best combined predictive value with a sensitivity of 15% and a specificity of 100%. 
When compared to normal values (22,23) a significant increase was detected with respect to 
the number of leukocytes, the percentage of lymphocytes and midfraction (consisting of 
No recent IM Recent IM 
n=199 n=27 
percentage percentage 
92 
50 
51 
45 
3 
34 
12 
23 
6 
17 
1 
3 
7 
2 
7 
1 
96 
89 
89 
78 
74 
56 
48 
41 
26 
11 
11 
7 
7 
4 
0 
0 
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Table 2. Results of laboratory assays differing from normal values in patients with and 
without infectious mononucleosis 
Laboratory 
assay 
number of leukocytes 
% of lymphocytes8 
% of midfraction a 
% of granulocytes8 
atypical lymphocytes'5 
hemoglobin 
mean cell volume 
thrombocytes 
alanine transaminase 
Results 
+ / -
+ 
+ 
•f 
-
+ 
-
+ / -
-
+ 
No recent IM 
n=199 
percentage 
14 
10 
2 
11 
16 
12 
1 
8 
9 
Recent IM 
n=27 
percentage 
54 
76 
28 
78 
81 
15 
0 
19 
93 
increase 
decrease 
significant difference (p < 0.05) 
leukocyte differentiation (three part differentiation cell dyne-1600) 
manual differentiation 
atypical lymphocytes, monocytes, eosinophile-, basophile granulocytes and plasma cells), the 
number of atypical lymphocytes and the ALAT level (table 2). A significant decrease was 
detected for the percentage of neutrophile granulocytes and the number of thrombocytes. 
Stepwise logistic regression analysis showed that a combination of an increased ALAT level 
and a reduced percentage of granulocytes would result in the best combined predictive value 
with a sensitivity of 75% and a specificity of 100%. The estimated probability of having IM 
given different outcomes for these two parameters are given in table 3. The sensitivity rose to 
85% and the specificity decreased to 98% after combining these two variables with cervical-
and generalized-lymphadenopathy. 
Table 3. Individual contribution of ALAT and percentage 
of granulocytes: estimated probability (logistic model) 
of having infectious mononucleosis 
ALAT % granulocytes ρ 
t i 0.92 
0.0025 
Î = 0.255 
i 0.08 
t : increase, 1 decrease in relation to normal value 
= : normal value 
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Table A. Patients with false positive or false negative observations in tests for heterophi le 
antibodies 
Test 
case number 
age in years 
hematologic 
A LAT 
fatigue 
lymphadenopathy 
fever 
pen-orbital 
swelling 
duration of 
symptoms in days 
IgG-VCA 
IgM-VCA 1 val 
2 val 
IgA-VCA 
anti-EA 
anti-EBNA 
PBD 1 val 
Ζ val 
BHL 1 val 
2 val 
MOD 1 val 
2 val 
* : sample w 
. sample w 
lue 
lue 
ue 
Lue 
ue 
lue 
ue 
lue 
ith 
PBD 
BHL 
MDD 
163 
ID 
= 
" 
+ 
+ 
+ 
+ 
3 
64 
<8 
<8 
<8 
<8 
<2 
<8 
<8 
<8 
<8 
neg 
neg 
marginal va 
ith detectable 
false 
BHL 
MDD 
137 
9 
a 
a 
+ 
+ 
+ 
-
120 
32 
32 
32 
<8 
32 
<2 
64 
128 
<8 
960 
neg 
neg 
ι lue 
negative 
MDD 
130 
18 
a 
a 
+ 
-
-
-
36 
64 
32 
32 
8 
64 
<2 
128 
256 
960 
960 
neg 
pos 
IgM antibodies for 
MDD 
166 
19 
a 
a 
+ 
+ 
-
-
7 
32 
32 
16 
8 
<8 
<2 
1024 
256 
960 
960 
neg 
pos 
ToxoBlasma 
PBD 
BHL 
38a 
22 
= 
= 
_ 
+ 
-
-
60 
128 
<8 
<8 
<8 
<8 
+ 
128 
32 
240 
30 
neg 
pos 
oondii 
false 
PBD 
BHL 
MDD 
2 4 8 a 
16 
= 
= 
+ 
-
+ 
-
7 
128 
<β 
<β 
8 
16 
+ 
128 
32 
240 
<β 
pos 
neg 
positive 
PBD 
BHL 
MDD 
2 0 0 b 
11 
a 
a 
+ 
-
+ 
-
13 
32 
<8 
<8 
<β 
16 
+ 
1024 
1024 
960 
960 
pos 
pos 
MDD 
30 
21 
= 
a 
+ 
+ 
+ 
-
40 
64 
<8 
<8 
<8 
32 
+ 
32 
64 
0 
<8 
pos 
pos 
PBD 
BHL 
MDD 
n o r m a l 
consistent with IM 
present 
absent 
Paul-Bunnell-Davidsohn test 
hemolysin test 
Monosticon Dri-dot test 
One sample gave a false-negative reaction in all three tests for heterophile-antibody detection 
(table 4). Another serum was false-negative both in the BHL test and the MDD test and two 
other sera in the MDD test only. False-positive results in both the PBD test and the BHL test 
were obtained in three samples (table 4). A marginal titer was found in sera from patients 
number 38 and 248, while IgM-antibody to Toxoplasma gondii was detected in patient 
number 200. Two of the three false positive sera in the PBD and the BHL test were also 
false-positive in the MDD test with one sample being positive in the MDD test only. 
The sensitivity of the PBD test was 96% and that for BHL and MDD test 93% and 85% 
respectively (table 5). The specificity of all tests was 98%. The positive predictive value of 
the PBD test, of the BHL test and of the MDD test was 90%, 89% and 88%, respectively. The 
negative predictive value of the PBD and the BHL test was 99% and of the MDD test 98%. 
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TabLe 5. Sensitivity, specif ic i ty, positive predictive value (PV+Ì and negative predictive vaLue (PV-) 
of heterophil Le antibody detection tests in relation to the definit ion of a recent EBV infection. 
Test 
PBD 
BHL 
MDD 
true 
positive 
η 
26 
25 
23 
false 
pos 111 ve 
η 
3 
3 
3 
true 
negative 
η 
191 
191 
191 
false 
negative 
η 
1 
2 
A 
sensi­
tivity 
% 
96 
93 
85 
speci­
ficity 
Ϊ 
98 
98 
98 
PV+ 
X 
90 
89 
88 
PV-
% 
99 
99 
98 
Sera with false-positive or false-negative results were all re-examined. A positive result in 
false-negative sera was detected in one serum by the BHL test and in two sera by the MDD 
test (table 4). On reexamination in the PBD and BHL test negative results in false-positive 
sera were obtained in two sera each, in the MDD test in one sample (table 4). 
IgM antibody to CMV was detected in 3 (1.4%), and to Toxoplasma gondii in 5 (2.3%) of the 
221 tested samples. 
5.5 DISCUSSION 
Primary EBV infection was detected in patients between 8 and 26 years of age as has been 
reported by other investigators (14,24-27). The most frequent symptoms and signs in our 
patients were fatigue, lymphadenopathy, sore throat, headache, fever and myalgia. Using 
stepwise logistic regression analysis sore throat and peri-orbital swelling were selected as 
having the best predictive value. However, the 15% sensitivity of these selected parameters 
for IM and the low incidence of peri-orbital swelling strictly limit their diagnostic value. No 
serologic evidence of a primary EBV infection was detected in 13 patients (group ii and iii) 
who were free of symptoms. Eight of these had had contact with an IM patient. These results 
underline that it is not necessary to perform laboratory tests in patients without clinical 
symptoms. The prevalence of IgA-VCA (81.5%) and anti-EA (85.2%) corresponds well with 
data reported by others (25-27). No relevant information was obtained by detection of IgA-
VCA and anti-EA. 
The results of the ALAT test and more than half of the hematologic findings were 
significantly different between sera of patients with and without IM. However, with stepwise 
logistic regression analysis only a decreased percentage of granulocytes and an increased 
ALAT level were selected together showing a combined sensitivity of 75% and a specificity 
of 100%. When combined with clinical symptoms these tests gave a slightly increased 
sensitivity (85%) but a slightly decreased specificity (98%). 
False-negative reactions in all three tests for heterophile antibodies were obtained in serum 
from a 10 year old boy with symptoms of fatigue, headache, sore throat, fever, peri-orbital 
swelling, lymphadenopathy but normal hematologic and ALAT values. The serum was taken 
three days after onset of symptoms, which might explain the negative reaction for 
heterophile antibodies. A second sample could not be obtained. The three remaining false-
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negative reactions were detected in samples from patients with symptoms of disease and 
corresponding hematologic and ALAT values (table 5). One BHL test and two of three MDD 
tests were positive when repeated. This might have been due partly to laboratory error, 
possibly that of interpretation. Of the four sera with false-positive reactions two had low-
positive titers in the PBD and BHL test. One sample was obtained sixty days after onset of 
lymphadenopathy and the second seven days after onset of fatigue and fever. Both patients 
had normal hematologic anà ALAT values. False positive reactions have been described in 
sera from patients with other illnesses (5-8) but the presence of heterophile antibodies may 
also have been the result of an infection several months previously. However on 
reexamination the titer for both sera was 1:32 in the PBD test and negative in the BHL test. 
This is almost certainly due to faulty interpretation of the test. A third false-positive reaction 
was obtained in a patient with a recent Toxoplasma gondii infection. The fourth false-
positive MDD test, was found in serum obtained 40 days after onset of symptoms in a patient 
with symptoms and signs consistent with IM but with normal hematologic and elevated 
ALAT values. No explanation could be found. 
The sensitivity of heterophile antibody tests was 96%, 93% and 85% for the PBD, BHL and 
MDD test, respectively, with corresponding positive predictive values of 90%, 89% and 88%. 
Similar results have been described by others for the PBD test (14). Our true positive results 
for the MDD test were both lower (5,14) and higher (10) in relation to data of other 
investigators. This might be explained by the type of slide test used. The specificity (98%) 
and negative predictive value (98-99%) were about equal for all heterophile antibody tests. 
The low prevalence of IgM antibody to CMV (1.4%) or Toxoplasma gondii (2.3%) indicates 
that these tests should be used when EBV serology is negative in patients with signs and 
symptoms of IM. 
Our study shows that the PBD test for heterophile antibodies is a suitable assay for diagnosis 
of IM in general practice for individuals older than 6 years (28,29), and is more sensitive 
than the MDD test. Tests should be carried out in samples from symptomatic patients only. In 
sera not containing heterophile antibodies additional tests should include a differential 
leukocyte count with atypical lymphocyte determination and ALAT. Should there be a 
discrepancy between follow-up of clinical symptoms and laboratory determinations, specific 
serology for EBV, CMV and Toxoplasma gondii should be performed. 
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CHAPTER 6 
PREVALENCE OF ANTIBODIES TO HUMAN HERPESVIRUSES IN A PART OF THE 
DUTCH POPULATION 1 
6.1 SUMMARY 
The prevalence of antibodies to Epstein-Barr virus (EBV), herpes simplex virus (HSV), 
varicella-zoster virus (VZV), cytomegalovirus (CMV) and human herpesvirus type 6 (HHV-
6) was determined in sera from 802 persons between 0 to 65 years of age. The maximum 
prevalence and age at which it occurred was 98% for EBV at 30 years, 99% for VZV at 9 
years, 80% for HSV at 45 years, 60% for CMV at 65 years and 96% for HHV-6 at 2 years. 
The prevalence and titers of antibody to HHV-6 decreased after 30 years of age whereas the 
antibody prevalence for EBV, VZV and HSV remained at peak levels. The prevalence of 
CMV continued to rise with increasing age. In adults, Ig M and IgA antibody against the viral 
capsid antigen and antibody to early antigen of EBV was found in 0%, 24% and 30%, 
respectively. These results conform to those found in other industrialized countries. 
1
 G. Weers-Pothoff, Th.M. de Boo, M.J. Willemse, F.W.A. Heessen, A.M. van Loon. 
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6.2 INTRODUCTION 
Epstein-Вагт virus (EBV) has a worldwide distribution. However, significant differences 
exist in the prevalence of antibodies against EBV. The prevalence increases with age (1-7), is 
often high in early childhood associated with low socioeconomic conditions (6,8-12), and 
depends upon the geographical area (2,3,11,12). The observed differences are most 
pronounced in children. In Alaska, the prevalence of antibody to EBV within the 3- to 10-
year age group was 100% (11), whereas in Australia 44% of children of the same age group 
had antibodies (3). In adolescence, these differences disappear. In Europe and North America 
90% to 97% of adults over 60 years of age have antibodies to EBV (13). 
In common with EBV, the other members of the herpetoviridae (varicella-zoster virus tVZV], 
herpes simplex virus type 1 [HSV-1], type 2 [HSV-2], cytomegalovirus [CMV], and human 
herpesvirus type 6 [HHV-6]) also have a worldwide distribution and ase opportunistic 
pathogens. Furthermore EBV, and CMV have a number of clinical symptoms in common e.g. 
lymphadenopathy. 
No data are available for the prevalence of HHV-6 antibodies in the Netherlands. For the 
other herpesviruses data are only partially available (14-19). Previous studies were mostly 
performed in small groups (14-16), sometimes with less sensitive methods (e.g. a 
complement-fixation [CF] test, 16) and more than 10 years ago (14,15). More recent data are 
available for the adult population only (17-19). Therefore, we determined the prevalence of 
IgG antibodies to EBV, VZV, HSV, CMV and HHV-6 in part of the Dutch population 
between 0 and 65 years of age. Antibodies to EBV and HHV-6 were determined by an 
immunofluorescence assay and to VZV, HSV and CMV by an indirect ELISA. In part of the 
sera IgM- and IgA-antibodies to the viral capsid artigen (VCA) of EBV and antibodies to the 
EBV-early-antigen (anti-EA) were determined. In addition in part of the sera the titers of 
IgG antibodies to HHV-6 were determined. 
6.3 MATERIALS AND METHODS 
6.3.1 Sera 
Serum samples were collected consecutively from 385 children (237 boys and 148 girls) aged 
1-17 years, admitted to the University Hospital Nijmegen for various reasons between april 
1987 to January 1988 (kindly provided by Dr. V. Kunst, Blood Transfusion Service, 
University Hospital Nijmegen). None of these children had symptoms or signs related to 
infectious diseases or immunosuppression. Sera from 417 healthy blood donors (264 men and 
153 women), between 18 and 65 years (kindly provided by Dr. H. Olthuis, Red Cross Blood-
bank, Nijmegen) were also collected consecutively. All sera were stored at -20oC until 
testing. 
Assays for IgG antibody to VCA, antibody to EBV nuclear antigen (anti-EBNA) and assays 
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for IgG antibody to VZV, HSV and CMV were carried out in all samples and for HHV-6 
when suflicient material was left. Assays for IgM-VCA, IgA-VCA and anti-EA to EBV 
were carried out in 181 serum samples chosen at random from individuals above 20 years of 
age. 
6.3.2 Antibody detection methods 
IgG-, IgA-, IgM-VCA and anti-EA to EBV were determined by an indirect 
immunofluorescence assay (IF) on P3HR1-derived НН514-СІ6 cells (20, kindly provided by 
Dr. J. Middeldorp, originating from Dr. G. Miller). The cells were grown at 360C in flat 
bottom tubes (Corning 25110) in a 1:1 (v\v) mixture of RPMI-I640 (Gibco) and HAM's F 1 0 
medium (Flow Laboratories) supplemented with 5 mM L-glutamine, 5% heat-inactivated 
foetal calf serum (FBS, Flow Laboratories), 50 ug/ml gentamicin and 100 U/ml penicillin 
(21). HH514 cells were induced for VGA expression by culturing the cells at a concentration 
of 1.5xl06 cells/ml for 6 days at 330C in medium containing 3 mM sodium butyrate, and 20 
ng/ml 12-0-tetradecanoyl-phorbol-13-acetate (TPA, Sigma). For EA expression 1.5xl06 
cells/ml were cultured for 3 days at 330C in the same medium to which 200 ug/ml 
phosphonoacetic acid (PAA) was added (22). Cell smears were fixed with acetone for 10 min 
at -20oC. The assay was performed in a single serum dilution of 1:8 as described by Henle et 
al (23) using FITC-labelled goat F(ab')-fragments specific for human IgG, IgM, or IgA (all 
from Tago). In the assay for IgM-VCA the sera were pretreated with Gull Sorb (Gull 
laboratories) to remove excess of IgG antibodies. 
Anti-EBNA was determined on Raji cells, which were grown in flat bottom tubes in medium 
consisting of RPMI-1640 with 10% FBS, 50 ug/ml gentamicin, and 100 U/ml penicillin. 
Three days after refreshing the culture, cell smears were made and fixed with acetone for 10 
min at -20oC followed by methanol for 30 min at -70oC. Anti-EBNA was detected by the 
anticomplement-immunofluorescence technique (ACIF) (24,25) in a serum dilution of 1:2 and 
1:8 using guinea pig complement and FITC-conjugated goat anti-guinea pig C3c globulin 
(GAGp/СЗс, Nordic). 
When sufficient material was left antibody to HHV-6 was determined. Thus, 725 samples 
were available for determination by an indirect IF on J JHAN lymphocytes (kindly provided 
by Dr. R.S. Tedder). Cells were infected with HHV-6, and grown in medium consisting of 
RPMI-1640 with 10% FBS, 50 ug/ml gentamicin, and 100 U/ml penicillin at 360C. When 
more than 50% of the cells showed cytopathic effect, approximately 2 weeks after infection, 
smears were made and fixed with acetone for 20 min at -20oC. In order to minimize non­
specific reactions sera were inactivated at 56CC for 30 min and thereafter diluted 1:10 with a 
cell suspension prepared by freezing and thawing of 2.5xl05 uninfected J JHAN cells/ml. 
After 30 min the suspension was centrifuged at 750xg for 5 min. The supernatant was further 
diluted to 1:20 and 1:40, and overlaid on the HHV-6 infected J JHAN cells. After incubation 
at 360C for 30 min, the cells were washed twice with phosphate buffered saline (PBS) at pH 
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Table 1. Number of tested blood samples by age group. 
age group number age group 
10 
11-12 
13-14 
15-16 
17-18 
19-20 
21-25 
26-30 
31-40 
41-50 
>51 
total 
num 
15 
22 
29 
42 
28 
31 
49 
42 
82 
84 
109 
802 
0 -<0.25 
0.25-O.5 
0.5 -<1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
66 
14 
18 
41 
20 
17 
20 
15 
13 
11 
20 
14 
7.2 and further incubated with FITC-labeled goat F(ab')2-fragments specific for human IgG 
(Tago) at 360C for 30 min. Following another two washes with PBS the cell smears were 
counterstained with Evans blue for 5 min. In accordance with suggestions by Briggs et al (26) 
we considered sera with a repeatedly weakly reactive pattern in a dilution 1:20 as being 
negative (26). A positive and negative serum, a buffer and an immunoglobulin control, were 
included in all tests. Antibody titers were expressed as the reciprocal of the highest dilution 
yielding detectable immunofluorescence. 
Antibody to VZV, HSV and CMV was measured by ELISA as described previously 
(27,28,29). Sera within 20% of the cut-off value were reexamined. 
6.3.3 Statistical analysis 
For statistical analysis the Chi square test was used. 
6.4 RESULTS 
The relation between age and prevalence of antibodies to all herpesviruses is given in Figures 
la to le. No relevant differences were found between the male and female population. 
Therefore, the data are presented together. The number of tested samples for each age group 
is given in table 1. 
Over 80% of the newborns had maternal IgG-VCA antibody to EBV (Figure la). The 
prevalence of IgG-VCA declined during the first half year of live and subsequently increased 
until the age of 30. The increase seemed steeper from 1 to 5 years and from 10 to 18 years. 
Finally, in 98% of the individuals from 30 to 65 years this antibody was detected. As 
expected, the prevalence of anti-EBNA followed an almost identical pattern (data not 
shown). Seven sera (1.1%) had IgG-VCA antibody but no anti-EBNA. IgM-VCA to EBV was 
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Figure la. Age related prevalence of IgG-VCA to EBV (with 1 standard deviation [SD]) as 
determined by IFA in 802 sera. 
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Figure lb. Age related prevalence of IgG antibody to VZV (with l SD) as determined by 
ELISA in 802 sera. 
not detectable in any of the 181 sera from donors over 20 years of age. IgA-VCA was found 
in 43 (24%) and anti-EA in 55 (30%) of these sera. Sera containing IgA-VCA or anti-EA 
antibody were titrated. The titer of IgA-VCA ranged from 8 to 256, and of anti-EA from 8 
to 128. When the data were analyzed for different age groups, no significant relationship was 
found between antibody and age group. 
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Figure le. Age related prevalence of IgG antibody to HSV (with 1 SD) as determined by 
ELISA in 802 sera. 
F i g u r e id IgG e n l i D o d y to CWV 
Freque псу (Й6) 
f l l ι 1 ι 
30 
Age ( y e a r s ) 
Figure Id. Age related prevalence of IgG antibody to CMV (with 1 SD) as determined by 
ELISA in 802 sera. 
VZV antibody prevalence had all the characteristics of a disease of childhood (figure lb). 
The prevalence of maternal VZV antibody in newborns was similar to that for EBV. After 
the decline of these antibodies the prevalence increased sharply between 3 and 8 years of age 
resulting in a 99% prevalence at the school age. 
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Figure le. Age related prevalence of IgG antibody to HHV-6 (with 1 SD) as determined by 
IFA in 725 sera. 
Figure 2. Geometric mean titer with 1 SD of IgG antibody to HHV-6 in relation to age as 
determined in a-select choosen samples from 137 individuals form Oto 65 years of age. 
The number of newborns with maternal antibody to HSV was approximately 20% lower 
compared to EBV (figure 1c). After the loss of maternal antibody there was a steady rise in 
antibody up to 30 years of age, followed by a stabilization. The maximum percentage of sera 
with HSV antibody was approximately 80%. 
CMV infections appear to occur less frequently than infections with other herpesviruses 
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Table 2. Simultaneous presence of antibodies to human herpesviruses in 725 samples from 
individuals from 0 to 64 years. 
HHV-6 EBV VZV HSV CMV number % 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
+ 
+ 
-
+ 
-
-
+ 
+ 
+ 
+ 
+ 
-
-
+ 
-
-
-
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
+ 
-
+ 
-
-
+ 
+ 
-
-
+ 
-
-
-
+ 
-
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
-
+ 
-
-
+ 
+ 
-
-
-
+ 
+ 
-
-
+ 
-
-
-
-
+ 
+ 
+ 
-
-
+ 
+ 
-
-
+ 
-
-
+ 
-
-
+ 
+ 
+ 
-
-
-
-
-
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
-
-
-
-
-
+ 
-
+ 
+ 
-
-
+ 
+ 
-
-
+ 
+ 
+ 
+ 
-
-
-
+ 
118 
112 
100 
45 
51 
51 
42 
35 
24 
21 
17 
13 
12 
9 
8 
8 
7 
7 
7 
7 
6 
5 
4 
4 
3 
3 
2 
2 
2 
725 
16.3 
15.4 
13.8 
6.2 
7.0 
7.0 
5.8 
4.8 
3.3 
2.9 
2.3 
1.8 
1.7 
1.2 
1.1 
1.1 
1.0 
1.0 
1.0 
1.0 
0.8 
0.7 
0.6 
0.6 
0.4 
0.4 
0.3 
0.3 
0.3 
HHV-6=human herpesvirus type 6,EBV=Epstein-BaiT virus, VZV=varicella zoster 
virus,HSV=herpes simplex virus, CMV=cytomegalovirus, + = positive, - = negative. 
(figure Id). Antibody prevalence increased from 10% after loss of maternal antibody to 
approximately 300/o in adolescence and continued to rise slowly to 60% between 51 and 65 
years of age. 
Antibody prevalence to HHV-6 was determined in 725 sera (figure le). The prevalence in 
newborns was 67% and decreased to 46% between 4 and 6 months of age. By one year the 
prevalence increased to 90% and remained at this level until 30 years. Thereafter, a slight 
decrease in the prevalence of antibody was observed. The geometric mean titer (GMT) of 137 
samples (91 sera from persons between 0 and 17 and 46 sera from persons between 18 and 65 
years of age) are given in figure 2. The highest GMT was detected in the 1 to 2 year age 
group. After 35 years of age there was a slow decline in GMT. 
Simultaneous prevalence of antibodies to the herpesviruses is given in table 2. 
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Antibodies to all herpesviruses were detected in 118 (16.3%) persons. Excluding 15 samples 
containing maternal antibody, all, except nine (age 4, 5, 5, 11, 12, 14, 15, 15 and 15 
respectively), were over 19 years of age. Antibodies against four viruses were detected in 229 
(31.6%) persons, against three in 212 (29.9%), against two in 99 (13.7%), and against one in 
55 (7.6%). Of the 55 persons with antibody to one herpesvirus 35 had antibody to HHV-6. 
Thirty of them were under the age of 4. No antibodies to any of the herpesviruses were 
detected in 12 (1.7%) persons. They were all younger than 18 months. 
6.5 DISCUSSION 
Our results show that antibody prevalence is age-dependant. The differences in antibody 
prevalence of the herpes viruses are probably due to their different modes of transmission 
and exposure. The relative virulence of the viruses may also play a role. Usually the mode of 
transmission for VZV is by aerosol inhalation, for HSV, EBV and CMV by intimate contact, 
while EBV and CMV can also be transmitted via blood products. The route of infection for 
HHV-6 is not known. 
The prevalence of IgG-VCA antibody to EBV in this study corresponds with that observed 
by others in the Netherlands (14-17). As in other developed countries 50 to 60% of the 
population will have been infected by the age of 5 and between 80 to 90% by the age of 25 
(3-5,7,11). This is in contrast to economically less developed countries where between 80 and 
100% of the population will have been infected before the age of 4 (1,2,11,12,30-32). 
Although the numbers in the various age groups are small our results indicate a steeper 
increase IgG-VCA prevalence from 1 to 5 years and from 10 to 18 years. A higher incidence 
of infection resulting in steep rises in the antibody curve for these two age groups were also 
described by other investigators (33,34). We found that 7 sera contained IgG-VCA but no 
anti-EBNA. This has also been described by Horwitz (35) and may be due to a relative lack 
of sensitivity of the anti-EBNA assay. The prevalence of IgA-VCA in 43 (24%) samples 
concurs with data from Edwards and Woodroof (34) who found a prevalence varying from 5 
to 30% in adult populations. The presence of anti-EA in 55 (30%) samples was twice as high 
as that found by Sumaya in a rural community in Mexico (2). This might be explained by 
inter-laboratory variations. 
Since we used an ELISA technique it is not surprising that we found a considerably higher 
prevalence of VZV antibody (99% at the age of 9) than in previous studies in which the CF 
test was used (16,36,37). Antibody surveys performed with the CF test encountered problems 
with sensitivity and specificity. Within months after a primary VZV-infection, antibody 
titers detected by CF begin to fall and may reach sub-detectable levels (36,37). Children 
from 5 to 8 years are most commonly affected (36) and few persons escape infection before 
adolescence. The steep increase in antibody prevalence between 3 to 9 years may be 
explained by the contacts at school. These results confirm that varicella is a highly contagious 
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disease of childhood. 
The prevalence of HSV antibody in our study correlates well with that reported by other 
investigators (37). In a survey of a middle-class population in Seattle 40% of adults between 
25 and 29 years of age had complement-fixing antibodies to HSV. The antibody prevalence 
increased by about 1.5% per year up to the age of 50 leading to a prevalence of 84% (37). 
Other investigators reported a HSV antibody prevalence between 38% (CF test) and 100% (IF 
test) in adult populations in the Netherlands (14,15,17). 
In general, CMV is acquired early in life in developing countries; between 85 and 95% of 
children in Melanesia, Tanzania and China were seropositive by five or six years of age, and 
nearly 100% had antibody at early adolescence (1,38). This is in contrast to the studies in the 
United States and Western Europe where children of 5 to 6 years of age had a CMV antibody 
prevalence between 5 and 30% (39,40) and adults over the age of 50 had a prevalence 
between 52 and 80% (39,41,42). The prevalence in our study, 20% at the age of 5 to 6 years 
and a stable rise to 60% for people over 50 years, is in accordance with data from surveys in 
other Western countries, including the Netherlands (17,18). 
Data on HHV-6 antibody prevalence in the Netherlands were not yet available. In other 
countries, a prevalence has been reported from 41 to 100% in newborns. During the first half 
year of life the HHV-6 antibody prevalence drops sharply (26,43), but rises steeply between 
6 and 12 months till an antibody prevalence of 100% (44-46). Antibody prevalence as well as 
antibody titers have been shown to decrease with age also in several other studies (26,43-
45,47,48). 
Although we used other cells for antigen preparation and an IF assay instead of an ACIF 
assay our data are comparable with those from Brown et al (44) and Okuna et al (45). The 
data from Briggs et al (26) who used also J J HAN cells as a source of antigen show a lower 
prevalence but the same course of antibody for the various age groups. The decrease in 
antibody prevalence and titer above 30 years of age is remarkable in view of the rapid 
increase in antibody prevalence before the first year of live suggesting a high transmission 
and exposure rate. An explanation might be the detection limit of the test. 
Simultaneous presence of antibodies to the human herpesviruses was detected for almost all 
possible combinations of antibodies. The simultaneous prevalence of antibodies against at 
least EBV, VZV and HHV-6 in 77% of the tested persons confirms the more contagious 
nature of these viruses in relation to HSV and CMV. 
The exposure to herpesviruses in this part of the Netherlands is comparable to that in other 
developed countries. The maximum antibody prevalence for VZV and EBV is reached by 8 
and 30 years of age respectively being almost 100%. For both CMV and HSV there is an age-
related antibody prevalence reaching 60% and 80% respectively in adult life. Most people are 
infected with HHV-6 by the first year of life and after 30 years, the prevalence declines. 
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SUMMARY 
Development and evaluation of serological and virologica] techniques for EBV detection and 
their application in the diagnosis of EBV infections are subjects of study in this thesis. 
Additionally we examined the prevalence of antibodies to EBV and other human 
herpesviruses. 
In chapter 1 current knowledge about the virus is described with a review of the literature, 
followed by a short description of the aim of this study. 
For routine isolation of EBV a sensitive, rapid and standardized method is essential. 
Investigation of such method is described in chapter 2. With a standard inoculum we 
examined the susceptibility of lymphocytes from cord blood (LCB) and from adult EBV-
seronegative donors (LAD) as well as BJAB cells for infectious Epstein-Barr virus (EBV). 
Using cell transformation as the criterion for EBV infection, the virus titer of the standard 
inoculum varied between 1.5 and 7.5 ^ogTCIDgQ/ml for LCB and between 2.3 and 6.5 
^ o g T C I D ^ m l for LAD. When the presence of Epstein-Barr nuclear antigen (EBNA) was 
used as criterion for EBV infection, virus titers ranged between 2.5 and 9.5 ^logTCID^/ml 
for LCB, between 4.0 and 9.5 ^logTCIDgQ/ml for LAD and were maximal 3.5 
^logTCIDg/ml in BJAB cells. Infectious EBV was detected by EBNA 7 days earlier than by 
cell transformation, the maximum titer being reached two weeks after inoculation. LAD from 
a selected donor yielded a titer of 9 ± 0.5 ^logTCIDgo/ml in samples obtained at bimonthly 
intervals. On the basis of these results, for all further virus isolations lymphocytes from this 
donor were used. 
It is possible to transmit EBV by bone marrow transplantation in which B-lymphocytes play 
an important role as carrier. In chapter 3 we describe the effect of the separation of B-
lymphocytes from human stem cells by counterflow centrifugation on the reduction of EBV 
transfer probability. Large myeloid element (stem cells) fractions obtained from donor bone 
marrow by counterflow centrifugation, were examined for the presence of EBV. EBV was 
detected in stem cells from eight of the fourteen EBV-seropositive donors. Peripheral 
lymphocytes and throat washings were also investigated for the presence of EBV. In addition 
the EBV immune status was determined. In 8 of 14 EBV-seropositive donors the virus was 
detected in the stem cell fraction. No relation was found between EBV immune status, 
detection of EBV in throat washings or peripheral lymphocytes from the donor and the 
presence of virus in the stem cell fraction. No significant differences were observed in terms 
of immune status or virus excretion from the throat between patients receiving bone marrow 
with or without EBV. 
The kinetics of the specific antibody response to, and oropharyngeal excretion of, Epstein-
Barr virus (EBV) are discussed in chapter 4. These variables were studied longitudinally in 
three groups of individuals for 18 months after the onset of symptoms. Group 1 consisted of 
45 patients with infectious mononucleosis (IM) and group 2 of 11 patients who had signs and 
symptoms suggestive of IM but without serological confirmation of a primary EBV infection. 
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Group 3 comprised 20 healthy laboratory workers from whom single samples were obtained. 
IgM antibody to the viral capsid antigen (VGA) was present in the first serum samples of 
group 1 and persisted between 0.5 and 9 months. An IgA-VCA response was found in Т % of 
these patients and persisted for 18 months in 12% whereas the prevalence in group 2 was 
from 20% to 50% and in the third group 20%. IgG-VCA was detected in all sera from all 
groups. Antibody to the EBV-early antigen (anti-EA) was detected in 96% of the patients in 
group 1 and persisted in 65%. In group 2 it varied between 20% and 57% and in the third 
group it was 50%. While mean titers were significantly different for IgA-VCA and anti-EA 
the range was identical between groups 1 and 3. Therefore, they do not appear to be specific 
markers for a recent EBV infection in individuals. Antibody to the EBV nuclear antigen 
(anti-EBNA) was present in 35% of the first serum samples from patients of group 1 and in 
all samples after 10 months follow-up. Anti-EBNA was detectable in all sera from patients of 
both groups 2 and 3. Heterophile antibodies were detected in 91% of the first available 
samples from patients of group 1 and in none of group 2 and 3. 
All patients with IM excreted EBV from their throat as did 90% and 75% of those in groups 
2 and 3, respectively. Differences in viral titers between groups 1 and 3 were not significant. 
Confirmation of a primary EBV infection is most efficiently done by detection of IgM-VCA 
antibody, heterophile antibody or a seroconversion for anti-EBNA. Quantification of EBV in 
throat washing or detection of IgA-VCA and anti-EA is of little value. 
In chapter 5 the value of a large number of laboratory examinations that are often requested 
for by general practitioners in patients with symptoms of IM are evaluated. Sera of 221 
patients were examined for specific antibodies to EBV, cytomegalovirus, Toxoplasma gondii. 
heterophile antibodies, hematologic parameters and alanine transaminase (ALAT) activity. 
Twenty-seven (12.3%) patients were considered to have a recent primary EBV infection. 
Determination of heterophile antibodies in the sera of these patients by the Paul-Bunnell-
Davidsohn (PBD) test gave a sensitivity and specificity of 96% and 98%, by the beef 
hemolysin test of 93% and 98%, and by the Monosticon Dri-dot test of 85% and 98%, 
respectively. Using stepwise logistic regression analysis only a reduced proportion of 
granulocytes and an increase in ALAT were significantly correlated (p<0.05) with a primary 
EBV infection. Their combined sensitivity was 78% with a specificity of 100%. For signs and 
symptoms, sore throat and peri-orbital swelling were selected as having the best predictive 
value together having a sensitivity of only 15%. The results show that detection of 
heterophile antibodies should be the first test to perform in patients presenting to their 
general practitioner with signs and symptoms suggestive of IM. However, if clinical 
symptoms and the PBD test do not agree, further investigation is necessary to diagnose 
disease. 
A seroepidemiologic investigation of the prevalence of antibodies to EBV and other human 
herpesvirusses is described in chapter 6. Sera from 802 persons between 0 and 65 years of age 
were obtained. The maximum prevalence and age at which an antibody response occurred 
was 98% for EBV at 30 years, 99% for varicella-zoster (VZV) at 9 years, 80% for herpes 
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simplex (HSV) at 45 years, 60% for cytomegalovirus (CMV) at 65 years and 96% for human 
herpesvirus type 6 (HHV-6) at 2 years. The prevalence and quantity of antibody to HHV-6 
decreased after 30 years of age whereas the antibody prevalence for EBV, VZV and HSV 
remained at peak levels. The prevalence of CMV continued to rise with increasing age. In 
adults, IgM and IgA antibody against the viral capsid antigen and antibody to early antigen 
of EBV was found in 0%, 24% and 30%, respectively. These results conform to those found 
in other industrialized countries. 
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SAMENVATTING 
In dit proefschrift worden beschreven de ontwikkeling, toepassing en evaluatie van 
serologische en virologische methoden voor de diagnostiek en onderzoek naar de verspreiding 
van Epstein-Barr virus (EBV) infecties. Tevens is een sero-epidemiologisch onderzoek 
verricht naar de verspreiding van EBV en de overige humane herpesvirussen. 
In hoofdstuk 1 worden de diverse aspekten van het EBV besproken aan de hand van de 
literatuur, gevolgd door een korte beschrijving van het doel van deze studie. 
Voor routinematige isolatie van het EBV is een gevoelige, snelle en goed gestandaardiseerde 
methode noodzakelijk. Onderzoek hiernaar wordt in hoofdstuk 2 beschreven. Met een 
standaard inoculum, werd de gevoeligheid onderzocht van navelstrenglymfocyten (NSL), 
lymfocyten van EBV-seronegatieve donoren (LND) en BJAB cellen voor infectie met EBV. 
Bij microscopische beoordeling van de celtransformatie varieerde de titer van het standaard 
inoculum in de NSL tussen 1,5 en 7,5 ^logTCIDgo/ml en in de LND tussen 2,3 en 6,5 
^logTCIDg/ml. Wanneer detectie van het EBV kern antigeen (EBNA) als bewijs voor 
infectie werd gebruikt varieerde de titer in de NSL tussen 2,5 en 9,5 logTCID^/ml en in 
de LND tussen 4,0 en 9,5 '"logTCIDgo/ml, en was deze voor BJAB cellen maximaal 3,5 
^ogTCIOgg/ml. In alle celtypen werd bij gebruik van EBNA detectie twee weken na infectie 
de maximale titer bereikt. De herhaalbaarheid van de titer waargenomen bij gebruik van 
EBNA detectie, in vijf om de 2 maanden afgenomen monsters bij één donor, was 9±0,5 
^logTCIDgj/ml. Naar aanleiding van deze resultaten zijn voor alle virusisolaties uit 
keelspoelsels lymfocyten van deze EBV-seronegatieve donor gebruikt. 
EBV kan worden overgedragen bij beenmergtransplantatie (BMT). Hierbij spelen B-
lymfocyten een belangrijke rol. De kans op overdracht vermindert door verwijdering van de 
B-lymfocyten uit het te transplanteren beenmerg. In hoofdstuk 3 is onderzoek beschreven 
naar het effect van tegenstroom centrifugatie (TSC) op de verwijdering van EBV 
geïnfecteerde, respectievelijk gevoelige cellen in donorbeenmerg. De stamcel fractie, 
verkregen uit beenmerg van een donor na behandeling met TSC, werd onderzocht op de 
aanwezigheid van infectieus EBV. Bij 8 van 14 EBV-seropositieve donoren was het virus 
aantoonbaar in de stamcelfracties. Een relatie tussen de aanwezigheid van specifieke EBV 
antistoffen, virusuitscheiding in de keel en isolatie van virus uit perifere lymfocyten van 
donoren en de aanwezigheid van EBV in het beenmerg van donoren werd niet gevonden. 
Evenmin werd er een relevant verschil waargenomen tussen virusuitscheiding in de keel en 
antistofvorming tegen EBV bij patiënten die beenmerg met of zonder EBV ontvingen. 
In hoofdstuk 4 worden resultaten van onderzoek beschreven naar de waarde van de bepaling 
van EBV-specifieke antistoffen, heterofiele antistoffen, EBV uitscheiding in de keel en 
klinische symptomen voor de diagnostiek van primaire EBV infecties. De antistofrespons en 
virusuitscheiding werden gedurende 18 maanden onderzocht bij 3 groepen. Groep 1 bestond 
uit 45 patiënten met mononucleosis infectiosa (MI), groep 2 uit 11 patiënten met klachten 
passend bij MI maar zonder serologische aanwijzingen voor een recente infectie met EBV en 
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groep 3 uit 20 gezonde laboratorium medewerkers. In groep 3 werd éénmalig onderzoek 
gedaan. IgM antistoffen tegen het virus capside antigeen (IgM-VCA) waren aantoonbaar in 
alle eerste sera van groep 1 en in geen van de sera van groep 2 en 3. IgM-VCA persisteerde 
tussen 0,5 en 9 maanden na begin van de symptomen. Bij 78% van de patiënten in groep 1 
was IgA-VCA aantoonbaar in het eerste monster, na 18 maanden nog bij 12%. In groep 2 
varieerde de prevalentie tussen 20% en 50% en in groep 3 bedroeg deze 20%. IgG-VCA werd 
in alle sera van de drie groepen aangetoond. Antistoffen tegen het EBV vroege antigeen 
(anti-EA) werden in groep 1 bij 96% van de patiënten waargenomen en persisteerden in 65%. 
In groep 2 varieerde de anti-EA prevalentie tussen 20% en 57% en in groep 3 was deze 50%. 
Significante verschillen in gemiddelde titers voor IgA-VCA en anti-EA werden gevonden 
tussen groep 1 en 3. Deze verschillen zyn voor de beoordeling van titers in individuele 
patiënten van beperkte betekenis door de grote overlap in titerhoogten. Antistoffen tegen 
EBNA (anti-EBNA) xverden aangetoond in het eerste serum na ontstaan van de symptomen 
bij 35% van de patiënten van groep 1. Uiteindelijk was in het serum van alle patiënten van 
groep 1 anti-EBNA aantoonbaar. In de sera van de deelnemers van groep 2 en 3 was in alle 
monsters anti-EBNA aantoonbaar. Heterofiele antistoffen werden gevonden in 91% van de 
eerste monsters van groep 1 en in geen van de monsters van groep 2 en 3. 
Virus uitscheiding in de keel werd waargenomen bij alle patiënten van groep 1. Voor groep 2 
en 3 waren deze percentages respectievelijk 90% en 75%. Verschillen in titerhoogte tussen de 
groepen waren niet significant. Voor het aantonen van een recente EBV infectie blijft 
bepaling van IgM-VCA, heterofiele antistoffen of een seroconversie voor anti-EBNA de 
meest bruikbare methode. Kwantificering van EBV uitscheiding in de keel of aantonen van 
IgA-VCA of anti-EA is hierbij van beperkte waarde. 
In hoofdstuk 5 is onderzoek beschreven naar de betekenis van verschillende 
laboratoriumbepalingen die door huisartsen worden aangevraagd Ьц patiënten met 
symptomen passend bij MI. Sera van 221 patiënten werden onderzocht op specifieke 
antistoffen tegen EBV, cytomegalovirus en Toxoplasma gondii, heterofiele antistoffen, 
hematologische variabelen en alanine transaminase (ALAT). In 12,3% van de patiënten werd 
de diagnose MI serologisch bevestigd. De sensitiviteit en specificiteit voor een recente EBV 
infectie waren respectievelijk 96% en 98% voor de Paul-Bunnell-Davidsohn test, 93% en 98% 
voor de runderhaemolysine test en 85% en 98% voor de Monosticon Dri-dot test. Met 
stapsgewijze logistische regressie analyse werd een significante correlatie vastgesteld tussen 
een afname van het percentage granulocyten en een toename van de ALAT concentratie en 
MI. Bij de symptomen waren dit keelpijn en peri-orbitale zwelling. De resultaten wijzen erop 
dat in een huisartsenpraktijk voor de diagnostiek van MI bij personen boven de 6 jaar 
meestal volstaan kan worden met het aantonen van heterofiele antistoffen. In een beperkt 
aantal gevallen zal uitbreiding van laboratoriumonderzoek geïndiceerd zijn. 
In hoofdstuk 6 worden de resultaten beschreven van sero-epidemiologisch onderzoek naar het 
voorkomen van antistoffen tegen EBV en de andere herpesvirussen by 802 personen van 0 
tot 65 jaar. De maximale prevalentie en leeftijd waarop deze werden waargenomen waren 
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respectieveiyk 98% voor EBV op 30 jaar, 99% voor varicella-zoster (VZV) op 9 jaar, 80% 
voor herpes simplex virus (HSV) op 45 jaar , 60% voor cytomegalovirus (CMV) op 65 jaar en 
96% voor humaan herpesvirus type 6 (HHV-6) op 2 jaar. Prevalentie en titerhoogte van 
antistoffen tegen HHV-6 verminderden na de leeftijd van 30 jaar, terwijl de prevalentie van 
antilichamen tegen EBV, VZV and HSV stabiel bleef. Voor CMV antistoffen werd een 
kontinue toename gevonden tot 65 jaar. Bij volwassenen werden in respectievelijk 0%, 24% 
en 30% antistoffen aangetoond tegen IgM-VCA, IgA-VCA en anti-EA. Deze resultaten 
komen overeen met waarnemingen in andere geïndustrialiseerde landen. 
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